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ABSTRACT
Effects of Nicotine on Content of Corticotropin Releasing Factor 
     (CRF) in Rat Amygdala, Hypothalamus and Brain Stem
Sibonisiwe Ntini Masilela
Effects of 1.0 mg/kg and 0.4 mg/kg intraperitoneal nicotine on hypothalamic and
extra hypothalamic levels of corticotropin releasing factor (CRF) were examined in 104
rats.  CRF, a 41-amino acid peptide involved in responses to stress, fear and anxiety,
influences the same neurotransmitter systems as nicotine, a psychoactive component of
tobacco.  Radioimmunoassays revealed that in macro-dissected hypothalami, 15 minutes
treatment with 1.0 mg/kg nicotine significantly increased CRF content compared to no
treatment.  The 1.0 mg/kg dose did not elicit effects in macro-dissected amygdala and
brain stem.  With 0.4 mg/kg nicotine, no significant effects were observed in micro-
dissected hypothalamic paraventricular nucleus, amygdaloid and brain stem nuclei.  As
expected, plasma corticosterone levels were significantly increased with both doses of
nicotine.  Overall, no clear cut effects of nicotine on CRF were observed.  Micro-
dissection studies on specific nuclei using varying doses and time points would help
elucidate interactions of nicotine with CRF systems.  
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Corticotropin releasing factor, amygdala and nicotine
Corticotropin releasing factor (CRF) is a 41-amino acid peptide secreted mainly
by the paraventricular nucleus (PVN) of the hypothalamus (Owens and Nemeroff, 1991;
Vale, et al., 1981).  CRF is the chemical messenger by which the central nervous system
(CNS) controls the activity of the hypothalamic-pituitary-adrenal (HPA) axis and
therefore, is responsible for mediating the neuroendocrine response to stress.  CRF is also
released from other brain regions, particularly the amygdala, an almond shaped structure
located in the temporal lobe of the brain (Gray and Bingaman, 1996; Haines, 1991;
Owens and Nemeroff, 1991).  The median eminence which is served by the
paraventricular nucleus (PVN) of the hypothalamus has the highest levels of CRF.  The
PVN and central nucleus of the amygdala (CeA) also have considerably high levels
(Chappell, et al., 1986; Palkovits, et al., 1985; Skofitsch and Jacobowitz, 1985).  This
suggests that the neuropeptide is also an important mediator for the emotional responses
to stress and anxiety, which are mediated through the amygdala (Gray and Bingaman,
1996; Owens and Nemeroff, 1991).
The amygdala is rich in CRF expressing cell bodies and terminals, receptors and
CRF binding protein immunoreactivity (Gray, 1993; Gray and Bingaman, 1996; Owens
and Nemeroff, 1991).  Dense CRF cell bodies and terminals are located in the amygdaloid
central nucleus (CeA) while the basolateral nuclei have a high number of receptors (Gray
and Bingaman, 1996; Owens and Nemeroff, 1991; Sanakana, et al., 1986).  The amygdala
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has afferent and efferent neurons to and from structures including the hypothalamus,
brain stem nuclei, bed nucleus of stria terminalis and substantia nigra (Gray and
Bingaman, 1996; Swanson, et al., 1983; Uryu, et al., 1992).  These reciprocal projections
enable the amygdala to influence or be influenced by these brain regions through the
action of their neurotransmitters including norepinephrine, epinephrine, dopamine and
serotonin (Gray and Magnuson, 1987; Sanakana, et al., 1986; Van Bockstaele, et al.,
1996).  The amygdala also contains steroid receptors showing that it could be influenced
by glucocorticoids or other steroids (Swanson, et al., 1983).  Therefore, there are afferent
and efferent amygdaloid CRFergic neurons that are strategically localized to mediate both
autonomic and emotional responses to stress (Gray, 1992; Gray and Bingaman, 1996). 
Animal studies have shown CRF to be a neuromodulator in functions associated
with the amygdala.  Behavioral models of anxiety including social interaction, elevated
plus maze and fear potentiated startle, indicate that CRF is anxiogenic at increased levels
(Dunn and Berridge, 1990; Koob, et al., 1992; Liang, et al., 1992a; Liang, et al., 1992b). 
Reactions seen in electrical stimulation or lesions of the amygdala parallel those seen in
the injection or inhibition of CRF release, respectively.  Imbalances in levels of CRF in
the brain have been associated with psychiatric and affective disorders (DeSouza, 1995;
Nemeroff, et al., 1991; Owens and Nemeroff, 1991; Owens, et al., 1991).  Anti-anxiety
drugs such as benzodiazepines have been reported to induce modifications in CRF in the
hypothalamus, bed nucleus of stria terminalis (BNST), and septum.  In addition,
alprazolam and adinozolam decreased CRF immunoreactivity in the amygdala, piriform
cortex and cingulate cortex (Owens and Nemeroff, 1991; Owens, et al., 1989).  The
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question is whether or not other CNS drugs including nicotine exert their effects through
modulation of CRF levels in the brain.
Nicotine is a poisonous, volatile alkaloid derived from tobacco and is responsible
for many of the tobacco effects (McDonough, 1994).  Nicotine can be either a
psychostimulant or a depressant at high and low dose respectively (Balfour and
Fagerström, 1996; McDonough, 1994).  Neuronal nicotinic receptors (nAChRs) are the
primary receptors for the excitatory neurotransmitter acetylcholine and are located in
sympathetic and parasympathetic ganglia, and the adrenal cortex (Mycek, et al., 1992). 
The receptors exist in various brain regions particularly the hippocampus, cortex and also
in the amygdala and brain stem (Clarke and Pert, 1985; Fu, et al., 1998; Maren, 1996). 
The nAChRs consist of a family of heterogeneous receptor subtypes composed of - and
- subunits encoded by 12 different genes (Wada, et al., 1989; Luetje and Patrick, 1991;
Lukas, 1995).  The 42 receptor which is sensitive to nicotine and analogues is located in
both the somatodendritic membrane and  nerve terminal (Bylund and Yamamura, 1990;
Flores, et al., 1997; Watson, et al., 1987).  The receptor is a ligand gated ion channel
permeable to Na+, K+, and Ca2+, and mediates neurotransmission (McGehee and Role,
1995; McGehee and Role, 1996; Schwartz and Kandel, 1991).  
Nicotine and its analogues seem to influence brain neural systems that are
implicated in psychiatric and neural disorders; addictive mechanisms of nicotine have yet
to be determined (Balfour, 1982; Balfour and Fagerström, 1996).  In addition to the well-
demonstrated stimulation of acetylcholine release in the brain and peripheral nerves
(Armitage, et al., 1969; Balfour and Fagerström, 1996), animal studies have shown
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nicotine to act on various brain regions to modulate the secretion of neurotransmitters,
including dopamine, epinephrine, norepinephrine and serotonin (Benwell, et al., 1988;
Benwell, et al., 1990; Fu, et al., 1997; Fu, et al., 1998; Mifsud, et al., 1989; Nisell, et al.,
1994; Sugita, et al., 1992).  The rewarding properties of nicotine are believed to be
elicited through the interaction of neuronal nicotinic receptors with these neurotransmitter
systems (Benwell and Balfour, 1979; Dawe, et al., 1995; Rapier, et al., 1988; Rapier, et
al., 1990; ).  Nicotine is believed to exert differing responses in normal individuals
compared to depressed, and in stressed and unstressed animals (Balfour, et al., 1975;
Donnerer and Lembeck, 1990; Hall and Morrison, 1973).   One of the most prominent
effects of nicotine is the elevation of circulating ACTH and corticosterone, the stress
response hormones.  (Andersson, et al., 1983; Benwell and Balfour, 1982; Cam and
Bassett, 1983; Freund, et al., 1988).
Statement of problem
Studies have been done on the effects of nicotine on neurotransmitters in the
hypothalamus and some extrahypothalamic regions including the locus coeruleus,
hippocampus, cortex and striatum, effects of nicotine on the corticotropin releasing factor
(CRF) have scarcely been documented.  Whether or not nicotine exerts its effects in the
CNS by modulating CRF content is not known.  A recent immunocytochemical study by
Matta, et al., 1997, reported a dose dependent increased c-fos expression in CRF-positive
neurons in limbic structures after low dose nicotine treatment.  The proto-oncogene -fos
is an early detector for neuronal activity.  This suggests that nicotine stimulated neuronal
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activity in CRF neurons of extrahypothalamic regions, including central nucleus of the
amygdala, basal nucleus of stria terminalis, dorsal raphe, Barrington’s nucleus and also in
paraventricular nucleus of the hypothalamus.  The present study was undertaken to
examine the effects of nicotine on the content of CRF rich regions regions.
The objective of the study was achieved by examining effects of nicotine on CRF
content in rat amygdala, hypothalamus and brain stem, using two doses of nicotine at
different treatment time points. 
Significance of the problem
The ultimate goal is to find effects of chronic nicotine on CRF content in
hypothalamus and extrahypothalamic regions; this study will demonstrate whether or not
acute nicotine has effects on CRF which would open a way for investigating the chronic
effects.  This study is a step towards the studies that will compare responses to nicotine in
stressed and unstressed animals.  An elucidation of effects of nicotine on CRF systems
would also call for a study on the effects of nicotine withdrawal.  This work is a lead to
studies that will examine effects of prenatal exposure to nicotine, on CRF levels.
Hypotheses
1 There are significant increases in amygdaloid CRF levels for nicotine treated rats
compared to untreated and saline treated rats, at a given dose and time point.
2 There are significant increases in hypothalamic CRF levels for nicotine treated
rats compared to untreated and saline treated rats, at a given dose and time point.
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3 There are significant decreases in brain stem CRF levels for nicotine treated rats
compared to untreated and saline treated rats, at a given dose and time point.
4 There are significant differences in CRF levels per brain region at same dose of
nicotine and different time points. 
Assumptions
 The hypothesis of this study was based o the assumption that acute nicotine would
evoke changes in CRF content due to one or more of the following: (I) increased
release and utilization leading to decreased content, (II) increased synthesis,
processing or reuptake leading to increased levels, (III) decreased utilization and
degradation, leading to increased levels and (IV) inhibition of release leading to
increase levels.  The present study did not directly address these mechanisms but
only measured CRF content.  
 For untreated rats, CRF levels in a specific brain region would be similar at all
time points, but would vary depending on method of dissection. 
 For saline treated rats, CRF levels per brain region, would be similar at all time
points, but would vary depending on method of dissection. 
 Corticosterone levels for untreated rats would be similar at all time points. 
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Limitations of the study
(1) Two different doses were used with two different methods of dissection.  The
cryostat-micro-punch method targeted selected brain nuclei, while the macro-
dissection obtained the whole structure of the specific region.  Results from these
dissections can not necessarily be compared.
(2) The specificity of nicotine was not confirmed by pretreatment with nicotinic
receptor antagonist such as mecamylamine or dihydro--erythroidine. 
(3) Neither control nor test rats were handled prior to the test; handling all the rats
would  minimize non-specific stress.
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CHAPTER II
REVIEW OF THE LITERATURE
The amygdala
The amygdala is located in the temporal lobe of the brain and is part of the limbic system,
enveloped by the cortex, hippocampus, striatum, hypothalamus and lateral ventricles
(Amaral, et al., 1992; Kupfermann, 1991).  The amygdala is composed of heterogeneous
nuclei which are functionally distinct, making two subsystems which mediate responses
of anxiety and fear conditioning, that is, emotional memory storage and regulation of
memory storage in the hippocampus (Cahill and McGaugh, 1996; Cahill, et al., 1996;
McGaugh, et al., 1996).  The nuclei consist of the lateral, basolateral and basomedial
nuclei (collectively, the basolateral nuclei) and the central nucleus (CeA) (Amaral, et al.,
1992; Kupfermann, 1991; Maren, 1996).  The basolateral nuclei have a higher number of
CRF receptors compared to CeA and function as the primary sensory system of the
amygdala, with the CeA being the major output of the amygdala (with more CRF cell
bodies and terminals) mediating the anxiety and fear responses (De Souza, et al., 1985;
De Souza, 1995; Sanakana, et al., 1986; Swanson, et al., 1983).  Therefore, lesions of
either or both nuclei result in deficits in acquisition and expression of conditioned fear. 
Within the amygdala, therefore, the flow of information is from the basolateral nucleus to
the CeA (Maren, 1996).  Output from the CeA of amygdala is through two fiber bundles,
the stria terminalis (which projects to the basal nucleus of the stria terminalis) and the
ventral amygdalofugal pathway (Amaral, et al., 1992; Haines, 1991; Kupfermann, 1991).
The amygdala has afferent and efferent neurons to and from the hypothalamus,
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dorsal vagal complex, nucleus tractus solitarius (NTS), parabrachial nucleus,
mesencephalic nucleus, locus coeruleus and bed nucleus of stria terminalis (BNST) (Gray
and Bingaman, 1996; Haines, 1991; Swanson, et al., 1983; Uryu, et al., 1992).  These
reciprocal projections enable the amygdala to influence or be influenced by these brain
regions through their neurotransmitters, including norepinephrine, epinephrine, dopamine
and serotonin (Gray and Bingaman, 1996; Gray and Magnuson, 1987; Sanakana, et al.,
1986; Sugita, et al., 1992).  Even though the presence of efferents from the amygdala
have been established in the midbrain central gray, substantia nigra and ventromedial
medulla, afferents from these regions to the amygdala still need to be identified (Gray and
Bingaman, 1996).
Functions of the amygdala
 The amygdala, CRF, steroids and monoaminergic systems together play a role the
expression of behavioral, autonomic and neuroendocrine changes that occur in response
to stressful stimuli (De Souza, et al., 1985; Gray and Bingaman, 1996; Owens and
Nemeroff, 1991).  The amygdala mediates the perception of emotions and is associated
with behaviors connected with emotional and arousal components related to stress, fear
and anxiety; that is, defensive/aggressive responses, and also reproductive and feeding
behaviors (Goldstein, et al., 1996; Gray and Bingaman, 1996; Owens and Nemeroff,
1991; Maren, 1996).  The amygdala, therefore is believed to be influential in a variety of
psychopathological disorders such as depression, Tourette's syndrome, schizophrenia and
panic and anxiety disorders (De Souza, 1995; Gray and Bingaman, 1996; Jadresic, 1992;
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Owens and Nemeroff, 1991).  The amygdala is also linked to the development of
cardiovascular disease and gastric pathology (Gray and Bingaman, 1996; Junien and Gue,
1993; Tache, et al., 1993).
Direct outputs from the CeA to the hypothalamus and brain stem are believed to
mediate (through CRF) the symptoms of fear and anxiety which include, the arrest
reaction (cessation of behavior in anticipation of fight or flight), increased
arousal/vigilance and parasympathetic and sympathetic activation (increased heart rate,
sweating, decreased gastric motility (Davis, 1992; Gray and Bingaman, 1996; Owens and
Nemeroff, 1991).  Similarly, electrical stimulation of the amygdala in animals results in
reactions of fear, aggression, and activation of the autonomic nervous system (Davis,
1992; Gray and Bingaman, 1996; Owens and Nemeroff, 1991).  Bilateral lesions of the
amygdala produce disturbances of emotional behavior and block acquisition of fear
memory (as measured by fear potentiated acoustic startle responses); animals become
placid and display no reaction of fear, rage or aggression (Goldstein, et al., 1996;
Kupfermann, 1991; Roozendaal, et al., 1993).  Lesions of the amygdala block CRF-
potentiated acoustic startle (Liang, et al., 1992a).  Lesions of the CeA or bilateral
injection of benzodiazepines, gamma-aminobutyric acid (GABA; the major inhibitory
neurotransmitter in the brain) receptor agonists, to amygdala diminish the conditioned
fear and defensive freezing (Helmstetter and Bellgowan, 1993; Maren and Fanselow,
1996; Maren, et al., 1996; Owens and Nemeroff, 1991).
A number of studies have reported cellular mechanisms of fear conditioning. 
Amygdaloid synaptic processes that mediate acquisition and expression of learned fear are
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believed to be mediated by glutamatergic, GABAergic, noradrenergic and glucocorticoid
processes (Galvez, et al., 1996; Maren, 1996; Roozendaal, et al., 1996).  It is believed that
long term potentiation (LTP) plays a pivotal role in cellular mechanisms of fear
conditioning (Cahill, et al., 1996; Maren, 1996).  LTP is a "long  term increase in synaptic
transmission induced by high frequency stimulation of excitatory afferents" (Kandel, 1991;
Maren, 1996; Morris, et al., 1986).  Roozendaal, et al., (1996), studied adrenalectomized
rats with bilateral lesions into the basolateral, medial and central nucleus of the amygdala. 
The researchers concluded that learning and memory storage was modulated through
glucocorticoid receptors in the basolateral nucleus.  After studying changes in muscarinic
acetylcholine receptor immunoreactivity neurons in the amygdala,  Roozendaal, et al.,
(1997), concluded that fear conditioning was mediated through the dynamic plasticity of
muscarinic acetylcholine receptors in the amygdala.  Furthermore, Van der Zee, et al.,
(1997), in an immunocytochemical study, concluded that GABAergic and cholinoceptive
neural interactions in the CeA played an important role in fear induced responses.
Intra-amygdaloid infusions of norepinephrine or -agonists, after training animals
for conditioned fear, indicated the amygdala plays a critical role in mediating the memory-
modulating effects of endogenously released stress hormones and the effects of drugs that
affect neuromodulator systems (Cahill and McGaugh, 1996; McGaugh, et al., 1996). 
Stressful stimuli cause an activation of noradrenergic neurons and increased NE release
into the amygdala (Galvez, et al., 1996; Ida, et al., 1984; Tanaka, et al., 1991).  Sugita, et
al., (1992), also reported that serotonin (a neurotransmitter that modulates mood states and
is implicated in affective disorders), functions as a neurotransmitter in the amygdala.
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Neuronal transmission in the amygdala
Electrophysiological studies have demonstrated that afferent stimulation of the
basolateral nuclei results in both excitatory and inhibitory synaptic transmission (Gean and
Chang, 1991; Rainnie, et al., 1991a; Rainnie, et al., 1991b; Washburn and Moises, 1992). 
These findings have been confirmed by in vivo iontophoretic pharmacological studies on
the basolateral nuclei complex which showed that excitatory responses were mediated by
glutamate receptors, with GABA receptors mediating inhibitory responses (Li, et al., 1995;
Maren, 1996; Maren and Fanselow, 1995; Mello, et al., 1992).
The amygdala has various glutamate receptor subtypes: -amino-3-hydroxy-5-
methyl-4-isoxazolepropionate (AMPA), kainate  and N-methyl-D-aspartate (NMDA), and
also has glutamatergic cell bodies and neurons.  Glutamate (major excitatory amino acid in
the brain) is concentrated in the CeA (Farb and LeDoux, 1997; Farb, et al., 1992;
McDonald, 1996).  Glutamatergic terminals originate in the cerebral cortex and subcortical
structures that transmit sensory information to the basolateral nuclei of the amygdala, the
primary sensory region for anxiety and stress stimuli (Davis, 1992; Farb, et al., 1992).  
In the 1996 review, Maren concluded from the studies that “glutamatergic
projections synapse on both principal neurons, (class I) and inhibitory interneurons (Class
II), and that inhibitory neurons, in turn, send feed forward information to GABAergic
projections to principal neurons.”  Studies using an agonist of metabotropic glutamate
receptors revealed a role for these glutamate receptors in inhibitory processes (Maren, et
al., 1996; Rainnie, et al., 1994).  The ionotropic receptors for AMPA and NMDA mediate
13
excitatory responses.  This indicates that in the amygdala glutamate receptors generate
both excitatory and inhibitory responses (Campeau, et al., 1992; Maren, et al., 1996).  The
degree of ionotropic and metabotropic activation determines the excitability of cells in the
amygdala.  Researchers have reported that treatment of animals with glutamate receptor
antagonists diminish the acquisition and expression of fear conditioning (Fanselow and
Kim, 1994; Liang, et al., 1994).   As NMDA receptors and CRF receptors colocalize
(McDonald, 1996; Niehoff and Kuhar, 1983; Thomas, et al., 1985), it is likely that the two
neurotransmitters, CRF and glutamate, influence each other in amygdaloid processes. 
In addition to glutamate and GABA, the main sources of amygdaloid
neurotransmission, other neurotransmitters in the amygdala have been reported to
contribute to inhibition or excitation of neuronal activity.  These include CRF,
acetylcholine, endogenous opioids, norepinephrine and serotonin ( Gray and Bingaman,
1996; Owens and Nemeroff, 1991; Sugita, et al., 1992).  Researchers have observed
membrane hyperpolarization and inhibition of presynaptic transmission in the basolateral
complex after application of -opioid agonists, the cytokine, interleukin 1 and
anticholinesterase agent tetrahydro-9-aminoacridine (THA) (Sugita and North, 1993;
Wang, et al., 1995; Yu and Shinnick-Gallagher, 1994).  Membrane depolarization and
excitability have been observed in the rat basolateral amygdala after treatment with
muscarinic and nicotinic acetylcholine receptor agonist carbachol and THA (Wang, et al.,
1995; Womble and Moises, 1993).  Inhibitory effects have been observed after application
of CRF in both basolateral complex and CeA and this supports an autoregulatory role for
CRF in amygdaloid nuclei (Rainnie, et al., 1992).  Noradrenergic receptor agonists like
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isoproterenol have been shown to modulate cell excitability in the amygdala and also
enhance presynaptic calcium influx, thus facilitating neurotransmitter release (Gean and
Chang, 1992; Huang, et al., 1996).
Amygdaloid CRF and other neurotransmitters   
Monoaminergic terminals are colocalized with CRF dendrites and cell bodies in
the amygdala (Gray and Bingaman, 1996; Fallon and Ciofi, 1992; Van Bockstaele, et al.,
1996).  The amygdala has efferents and afferents to and from BNST, thalamus, lateral
hypothalamus, substantia nigra, central gray, nucleus raphe, parabrachial nucleus, locus
coeruleus, ventrolateral medulla and nucleus tractus solitarius (Fallon and Ciofi, 1992;
Moga and Gray, 1985; Van Bockstaele, et al., 1996).  Norepinephrine originates from the
locus coeruleus and nucleus tractus solitarius and epinephrine from the ventrolateral
medulla (Fallon and Ciofi, 1992; Fu, et al., 1998).  Dopamine originates from substantia
nigra and ventral tegmental area (Fallon and Ciofi, 1992; Haines, 1991).  Serotonin
originates from the central gray and nucleus raphe and acetylcholine is from septum and
basal forebrain (Fallon and Ciofi, 1992; Haines, 1991; Sugita, et al., 1992).  The
colocalization of CRF systems with these  neurotransmitters systems suggests that
different neurotransmitters potentially play modulatory role in CRF expressing neurons in
the amygdala (Gray and Bingaman, 1996; Haines, 1991).
GABA containing cells which express enkephalin immunoreactivity are located in
close proximity with CRF containing cells in the CeA (McDonald, 1996; Niehoff and
Kuhar, 1983; Thomas, et al., 1985).  The following peptidergic terminals are also
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colocalized with CRF neurons; enkephalin, substance P, cholecystokinin, neurotensin,
vasoactive intestinal peptide, neuropeptide Y and thyrotropin releasing factor (Gray and
Magnuson, 1992; Heilig, et al., 1994; Larsen, et al., 1993; Shimada, et al., 1989b). 
Substance P and CGRP are colocalized and likely to be contained within the same
terminals that synapse with CRF cells in the central nucleus (Larsen, et al., 1993; Shimada,
et al., 1985).
To mediate the physiological and behavioral responses to stress, CRF also interacts
with serotonergic and noradrenergic neurons (Liang and Lee, 1988; Sugita, et al., 1992;). 
Enhanced in vivo activity of tryptophan hydroxylase, (the rate limiting enzyme for 5-
hydroxytryptamine (5-HT) synthesis) in the dorsal raphe is seen after intra-amygdaloid
injections of CRF, actions that are blocked by CRF antagonist CRF9-41 (Beaulieu, et al.,
1986; Swiergiel, et al., 1993).  Stress increases norepinephrine (NE) levels in NE
producing brain regions and also in the amygdala (Tanaka, et al., 1991; Valentino, et al.,
1991).  These increases may be centrally mediated by CRF because CRF injections
intracerebroventricularly produced stress-like alterations in central noradrenergic
activation in locus coeruleus and parabrachial nucleus, an effect that is abolished by CRF9-
41 administration and bilateral lesions of CeA (Tanaka, et al., 1991).
An increase in noradrenergic cell firing in locus coeruleus, (LC) caused by CRF
administration, has been reported to result in anxiogenic effects as seen in open field
testing, and local release of CRF also triggered increased activation of NE release from LC
(Valentino, et al., 1991; Valentino, et al., 1983).  These and other studies point to
increased CRF as being anxiogenic and suggest that CRF possibly acts both directly and
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indirectly through other neurotransmitters to produce net anxiogenic effects (Liang, et al.,
1992a; Liang, et al., 1992b; Stenzel-Poore, et al., 1994).   
Manifestations of Amygdaloid CRF
The role of the amygdala and amygdaloid CRF in stress and anxiety has been
studied in behavioral models of anxiety (Gray and Bingaman, 1996; Owens and Nemeroff,
1991).  The amygdala is associated with behaviors involving emotional and arousal
components, such as defensive/aggressive, reproductive and feeding (Gray and Bingaman,
1996; Goldstein, et al., 1996; Maren, 1996; Owens and Nemeroff, 1991).  CRF injected
intracerebroventricularly (ICV CRF) or into the amygdala mimics the behavioral and
autonomic effects exerted by electrical stimulation of the amygdala (Davis, 1992; Dunn
and Berridge, 1987).  When injected into the amygdala, CRF has been shown to interfere
with exploratory behavior while enhancing inhibitory avoidance/avoidance learning (Liang
and Lee, 1988).  The acoustic startle (conditioned fear) responses are potentiated when
CRF is injected into the ventricles, but lesions of the amygdala block CRF potentiated
acoustic startle (Liang, et al., 1992a; Liang, et al., 1992b; Liang and Lee, 1988).  In
elevated plus maze, ICV CRF decreased exploratory behavior (Koob and Bloom, 1985). 
In novel environment, ICV CRF increased defensive freezing and grooming, decreased
locomotion and rearing, while potentiating acoustic startle responses (Dunn and Berridge,
1987; Dunn and Berridge, 1990).  In addition, Owens, et al., (1989), showed that
anxiolytics like adinozolam and alprazolam resulted in decreased CRF immunoreactivity
in the amygdala, piriform cortex and cingulate cortex.  These researchers also showed that
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these benzodiazepine induced modifications in levels of CRF in the hypothalamus, bed
nucleus of stria terminalis and septum.  These studies indicate an activation of endogenous
release of CRF in the amygdala during stress or anxiety like behaviors.  These findings
suggest that CRF is anxiogenic. 
The anxiogenic effects of high levels of CRF levels are manifested by increased
sensitivity to stressful stimuli, and are blocked by the CRF antagonist -helical CRF9-41
(Cratty, et al., 1995; Swiergiel, et al., 1992; Swiergiel, et al., 1993; Wiersma, et al., 1995). 
Injection of a small dose of -helical CRF9-41 into the amygdala reverses the stress induced
suppression of behavior in plus maze test of anxiety (Heilig, et al., 1994).  Tests on the
elevated plus maze show that CRF antagonists injected into the CeA reversed the
anxiogenic effects of alcohol withdrawal, reduced stress induced freezing and increased
exploratory behavior (Rassnick, et al., 1993; Swiergiel, et al., 1992).
Amygdala and hypothalamo-pituitary-adrenal (HPA) axis 
Hypothalamic mechanisms are reported to be modulated by limbic structures
including the amygdala and activation of NE neuronal projections to the amygdala is
believed to contribute to the stimulation of hypothalamus, in a process that involves -
adrenoceptors (Feldman and Weidenfeld, 1996a; Feldman and Weidenfeld, 1996b).  The
amygdala projects neurons directly to the PVN and innervates areas that contain neurons
which regulate the release of adrenocorticotrophic hormone (ACTH) in the anterior
pituitary (Feldman and Weidenfeld, 1996b; Gray, et al., 1989; Gray and Bingaman, 1996;
Owens and Nemeroff, 1991).  The PVN projects to the median eminence, which in turn
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releases CRF into the portal vessels to transport CRF to the anterior pituitary (Rivier and
Plotsky, 1986; Sawchenko and Swanson, 1990; Swanson, et al., 1983).  Hypothalamic
CRF triggers the release of ACTH from the anterior pituitary, causes increased
sympathetic outflow and also stimulates -endorphin for analgesic effects (Brown, et al.,
1982; Rivier, et al., 1982).  ACTH in turn triggers the release of glucocorticoids from the
adrenal cortex, which in turn can exert feedback inhibition on CRF (Feldman and
Weidenfeld, 1996b; Makino, et al., 1995; Owens and Nemeroff, 1991; Sapolsky, et al.,
1990).
 The amygdala is also indirectly connected to the PVN through projections to the
bed nucleus of the stria terminalis, which in turn sends a dense plexus of axon terminals to
the PVN (Gray and Bingaman, 1996; Owens and Nemeroff, 1991).  Other amygdaloid
connections via the brain stem nuclei also influence the PVN.  After electrical stimulation
of the amygdala, immunoreactivity of the c-fos proto-oncogene is observed in the
parvocellular part of the PVN indicating activation of neurons (Gray, et al., 1989; Petrov,
et al., 1994).  Lesions of the amygdala have been shown to attenuate ACTH release and
plasma corticosterone after the animal has been subjected to immobilization and
psychological stress, while electrical stimulation results in increased corticosterone levels
(Beaulieu, et al., 1986; Van de Kar, et al., 1991).  Allen and Allen, (1974), reported that
hypersecretion of ACTH which normally occurs after adrenalectomy is attenuated if the
amygdala is destroyed.  This indicates that the amygdala has a tonic excitatory effect on
the HPA axis in the absence of glucocorticoids.  
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CRF release, receptors and CRF binding protein
CRF Release
 CRF synthesis occurs in the parvocellular cell of the paraventricular nucleus
(PVN) (Vale, et al., 1981).  The cells project to the median eminence (ME) where CRF is
released into the portal circulation of the hypophysis to be transported to the anterior
pituitary to trigger ACTH release (Lightman and Harbuz, 1993).   Regulation of CRF
release in the hypothalamus has been studied and both protein kinase A  (PKA) and
protein kinase C (PKC) play a role in mediating CRF release (Hu, et al., 1992).  It has
been reported by Furutani, et al., (1983) and Castro, et al., (1991) that CRF is synthesized
as pre-proCRF, and after post-translational processing the active CRF is stored in vesicles
at terminals.  Gabr, et al., (1995),  reported a depolarization-induced, calcium dependent
release of CRF into the median eminence of stressed rats.   In their study of the possible
involvement of interleukin-2 and nitric oxide in CRF release, Raber,  et al., (1995) also
reported that both acetylcholine and norepinephrine induced the release of CRF from the
hypothalamus and amygdala.  The acetylcholine effect was antagonized by both atropine
and mecamylamine indicating the involvement of both muscarinic and nicotinic receptors. 
The norepinephrine effect was also antagonized by phentolamine and propranolol
suggesting that both  and  adrenergic receptors are involved in stimulation of CRF
release in amygdala and hypothalamus.  Plotsky, (1988) and Joanny, et al., (1989)
however, found that norepinephrine has either stimulatory or inhibitory effects depending
on predominant receptor subtype ( or ) localized on CRF neurons.   GABA, ACTH and
corticosterone have an inhibitory effect on CRF release (Calogero, et al., 1988; Lightman
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and Harbuz, 1993).   
For amygdaloid CRF, Cratty, et al., (1995), studied release of CRF from amygdala
minces of prenatally stressed rats and found that these rats had increased levels of the
peptide and released more CRF compared to rats from unstressed mothers.  Furthermore,
in a study on primary neuronal cultures, Cratty and Birkle, (1994), reported a
depolarization induced release of corticotropin-releasing factor in the amygdala.  Raber, et
al., (1995) used rat amygdala slices and reported that interleukin-2, acetylcholine and
norepinephrine play an important role in the induction of CRF release and also concluded
that this is possibly mediated through nitric oxide signaling.  In addition,
immunocytochemical techniques by Kasckow, et al., (1997) demonstrated that interleukin-
6 possibly acts to stimulate CRF release in the hypothalamus and amygdala. 
CRF receptors
In situ hybridization has enabled the identification of the two subtypes of receptors
CRF1 and CRF2 (De Souza, 1995; Dieterich, et al., 1997; Gray and Bingaman, 1996). 
CRF1 is densely located in the basolateral nucleus and moderate in the cortical, medial,
and lateral amygdaloid nuclei.  CRF2 is exclusive to the brain; the densest CRF2 mRNA
hybridization has been observed in the cortical and medial nucleus and moderate labeling
in the basolateral nucleus (Chalmers, et al., 1996; Lovenberg, et al., 1995).  CRF2 is
mainly found in the peripheral muscles including heart, skeletal muscle, adrenal medulla,
spleen, liver, kidney, prostrate and testes (Chalmers, et al., 1995; Lovenberg, et al., 1995).
Studies have shown that the CRF receptor is a seven member transmembrane
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protein linked to Gs proteins, with the generation of cyclic AMP (Battaglia, et al., 1987;
De Souza, 1995; Olianas and Onali, 1995).  Cyclic AMP generation results in ACTH
release in pituitary and is a substrate for potentiation by protein kinase C activators (Ca2+,
diacylglycerol and phosphatidyl serine) (Battaglia, et al., 1987; De Souza, 1995; Hu, et al.,
1992; Olianas and Onali, 1995).  Owens and Nemeroff,  (1991) reported that the presence
of CRF resulted in increased phosphoinositide turnover.  CRF may also activate the
calcium-calmodulin system (Murakami, et al., 1985).  This infers a possible cross-talk
between second messenger systems or synergistic effects between mechanism of ACTH
release and other neurotransmitters (Koch and Lutz-Bucher, 1991).  
Autoradiographic methods and in situ hybridization have been used to study CRF
binding sites and showed that the anterior pituitary has the highest density of CRF binding
receptors (De Souza, 1987; DeSouza, 1995; Owens and Nemeroff, 1991).  This is to be
expected since the pituitary is the site for ACTH release.  A significant number of binding
sites is also found in the olfactory bulb, cerebellum, cerebral cortex and striatum (De
Souza, et al., 1985; De Souza, 1987).  Autoradiographic methods have shown the highest
number CRF receptor binding in the basolateral nuclei of the amygdala compared to the
central nucleus which has the highest number of cell bodies and terminals instead
(Cummings, et al., 1983; De Souza, et al., 1985; De Souza, 1995; Meister, 1993; Swanson,
et al., 1983).  A high number of CRF receptors is also found in regions of the brain that are
targeted by the CeA, including BNST, PBN, LC, PVN and solitary nucleus (De Souza,
1987).  While CRF has an excitatory action at receptors in CeA targets, the neuropeptide
has both excitatory and inhibitory effects, and functions in autoregulation of CRF release
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in the CeA and PVN (De Souza, et al., 1985; Rainnie, et al., 1992). 
CRF binding protein
Deactivation of CRF occurs by degradation to smaller fragments by endopeptidases
or through binding by CRF binding protein (Behan, et al., 1993a).  A 37-kDa protein that
binds CRF to block the HPA axis was identified in human plasma and has been termed
CRF-binding protein (CRBP) (Behan, et al., 1993a).  CRF-binding protein and its mRNA
have been observed in rat brain, with large concentrations being found colocalized with
CRF in the amygdala (Behan, et al., 1993).  Increased levels of the CRBP mRNA have
been found in the medial amygdala and CeA (Behan, et al., 1993a; Potter, et al., 1992).  In
addition, Potter, et al., (1992) used dual labeling experiments to demonstrate that in the
central nucleus, both CRF immunoreactivity and CRBP are mainly expressed in the same
neurons, but not colocalized in the same neurons in other amygdaloid nuclei.  Although
studies on the specific functions of the protein in the amygdala are still needed, studies
done on hypothalamic CRBP indicate that the protein functions to limit CRF transport and
release, thus regulating activity of CRF neurons (Behan, et al., 1993b; Gray and
Bingaman, 1996; Potter, et al., 1992).
Brain stem nuclei
The CRF-containing brain stem nuclei include the locus coeruleus (LC),
parabrachial nucleus (PBN), nucleus tractus solitarius, Barrington's nucleus and the raphe
nuclei  (Gray, 1993; Valentino, et al., 1991; Valentino, et al., 1994).  The amygdalofugal
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pathway is the major CeA output bundle to the brain stem nuclei.  The putative role of
brain stem nuclei is in the modulation of sympathetic and parasympathetic activation, the
associated behavioral changes and also in nociceptive functions (Fu, et al., 1997; Gray and
Bingaman, 1996; Owens and Nemeroff, 1991).  CRF is found in regions that are involved
in pain processing, that is, periaquiductal gray (PAG), raphe nucleus and spinal cord
(Swanson, et al., 1983).  The LC is located in the upper pons and is the center for
norepinephrine containing neurons and projections.  Injections of CRF antagonists into LC
by Valentino, et al., (1991) demonstrated that this nucleus has a role in integrating CRF
and noradrenergic mediation of the stress response.  Koegler-Muly et al., (1993) showed
that electrolytic lesions of the CeA caused a threefold decrease in CRF levels in the LC,
thus implying a CRF pathway from CeA to locus coeruleus.  In 1986, Chappell reported
that stress caused an increase in content of CRF in the LC.  CRF from the amygdala is
believed to activate the locus coeruleus to trigger the production of catecholamines (Gray
and Bingaman, 1996; Owens and Nemeroff, 1991).  
CRF neurons are densely innervated by calcitonin gene related peptide (CGRP)-
containing terminals that originate from the parabrachial nucleus and thalamus (Harrigan,
et al., 1994; Shimada, et al., 1989a; Shimada, et al., 1992).  These studies indicate that the
interrelationships between amygdala and brain stem nuclei manifest a concerted role
involving CRF and brain stem neurotransmitters in the expression of behavioral and
autonomic components of anxiety, fear and defense responses. 
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 Effects of acute and chronic stress on CRF levels
The fluctuations in CRF levels in hypothalamus and amygdala that are observed in
acute and chronic stress and related pathologies may signify alterations in the synthesis,
active releasable pool, release or degradation of the neuropeptide (Chappell, et al., 1986;
Lightman, et al., 1993).  Chappell, et al., (1986) demonstrated that in the rat, acute stress
caused a two fold increase in CRF levels in the LC and a decrease in the median
eminence/arcuate nucleus and median preoptic nucleus.  Chronic stress maintained similar
changes in the locus coeruleus and median eminence/arcuate nucleus with decreased levels
in the dorsal vagal complex and increases in anterior hypothalamus and PVN (Chappell, et
al., 1986).  In situ hybridization techniques demonstrated that hypothalamic CRF mRNA
was reduced by corticosterone, confirming inhibition of CRF synthesis (Makino, et al.,
1995).  A study by Herman, et al., (1992), demonstrated that a 15 minute reduction in the
corticosterone negative feedback of hypothalamic CRF increases c-fos in the
hypothalamus resulting in detectable changes of CRF mRNA pools which were observable
in 60 minutes.  Chronic stress also down regulates CRF receptors in the hypothalamus
(Anderson, et al., 1993), which may be an adaptation to high levels of amygdaloid
CRFergic input, in addition to corticosterone’s feed back inhibition.  Ratka, et al., (1989)
studied the neuroendocrine regulation by Type I and Type II glucocorticoid receptors by
using antimineralocorticoid RU28318 and antiglucocorticoid RU38486 respectively, and
both antagonists prolonged the adrenocortical secretion following stress, indicating a
blockade of receptors to the feedback inhibition of corticosteroids.  
Immobilization stress affects both the amygdala and CRF systems, eliciting
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adaptive changes in CeA (Henke, 1983; Honkaniemi, et al., 1992a; Honkaniemi, et al.,
1992b).  Immobilization stress caused changes in the firing rate of amygdaloid neurons
(Henke, 1983) and also increased c-fos and corticosteroid receptor expression
(Honkaniemi, et al., 1992a; Honkaniemi, et al., 1992b).  This change in c-fos was in
conjunction with increased CRF mRNA in the CeA and hypothalamus (Mamalaki, et al.,
1992).  Kalin, et al., (1994) reported an increase in CRF mRNA content in PVN and
amygdala after restraint stress, suggesting that chronic stress elicits chronic elevations of
corticosterone, which manifests opposing effects to the putative inhibitory effects of
corticosterone on the PVN.  A down regulation of CRF receptors in amygdala can also
occur after chronic CRF administration and in mild stress (De Souza, 1995; Hauger, et al.,
1988; Hauger, et al., 1993).    
CRF in affective and neurological disorders
CRF plays a role in affective disorders and this is due to the persistent activation of
HPA axis, as has been observed in depressed patients (De Souza, et al., 1985; De Souza,
1995; Owens, et al., 1991).  There is evidence that CRF is hypersecreted in depressed
patients, thus causing increased ACTH and adrenal glucocorticoid activation (De Souza,
1995; Owens, et al., 1991; Owens and Nemeroff, 1993).  These researchers further
reported that CRF is increased in cerebrospinal fluid of depressed patients.  This
hypersecretion of CRF would ultimately lead to down regulation of CRF receptors, as
reported by Nemeroff, et al., (1988), after studying the  frontal cerebral cortex of suicide
victims.  CRF imbalances have been implicated in other neurological diseases including
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Alzheimer's, Parkinson’s and Huntington's diseases (De Souza, 1995; De Souza, et al.,
1986).  Alzheimer’s disease is manifested by a decrease in CRF content in the frontal,
occipital, temporal lobes of the cerebral cortex, amygdala, caudate and cerebrospinal fluid
while an up-regulation of CRF receptors is observed in some of these regions (De Souza,
1995; De Souza, et al., 1986).  In Parkinson's disease CRF concentrations are decreased in
the frontal, temporal, and occipital cortices and a significant decrease in caudate/putamen
CRF is seen in Huntington’s disease (De Souza, 1995).  CRF is also implicated to play a
role in satiation and weight control (Appel, et al., 1991; Le Feuvre, et al., 1991).
Glucocorticoid receptors
In vitro binding assays conducted by Reul and De Kloet, (1985) on microdissected
brain regions were the initial studies to demonstrate the presence of glucocorticoid
receptors in central nucleus, amygdala-hippocampal region and anterior amygdaloid area. 
Other studies using immunocytochemistry, autoradiography and in situ hybridization have
also reported the presence of glucocorticoid receptors in the amygdala (Honkaniemi, et al.,
1992a; Ahima and Harlan, 1990).  The inference from these studies is that glucocorticoids
can modulate CRF expressing neurons in the amygdala. 
A majority of CRF neurons that contain glucocorticoid receptor immunoreactivity 
descend to the brain stem autonomic regions and thus influence catecholaminergic
sectretion (Honkaniemi, et al., 1992a; Honkaniemi, et al., 1992b).  Circulating
glucocorticoids are believed to directly modulate production of CRF in the amygdala. 
Administration of increasing doses of corticosterone to adrenalectomized animals have
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been shown to correspond to as much as five fold increase in CRF mRNA expression in
the CeA of  the amygdala, while CRF mRNA in the hypothalamus decreased (Makino, et
al., 1994; Swanson and Simmons, 1989).  In animals and humans, increased anxiety or
fear have been reported to increase circulating levels of CRF and glucocorticoids
(Nemeroff, et al., 1991; Owens, et al., 1991).  Glucocorticoids therefore have direct effects
on the amygdaloid CRF expressing neurons, altering their activity during stress. 
 Circulating corticosterone
Corticosterone is the main glucocorticoid (equivalent of human cortisol) secreted
by the adrenal cortex of rats in response to stress and is a useful indicator of the
neuroendocrine response to stress in the laboratory animal (Shimizu, et al., 1983).  ACTH
is released in the pituitary in response to CRF release from hypothalamus and ACTH
triggers adrenal secretion (Rattner, et al., 1980).  Exposure to stressful stimuli including
drug injection, barometric shock, excessive handling, disease and abrupt changes in
temperature or environment, augment circulating corticosterone levels (Rattner, et al.,
1980; Shimizu, et al., 1983).  Concentrations of the hormone vary according to handling
techniques, sample collection method and time of day.  Generally, the baseline range for
rat corticosterone is between 50 and 400 nanograms/milliliter (ng/ml) (Shimizu, et al.,
1983).  In this study, corticosterone was measured as a marker for the presence of nicotine
in the system.  It was expected that nicotine would elevate corticosterone levels as reported
by other researchers (Benwell and Balfour, 1979; Cam and Bassett, 1983; Winders and
Grunberg, 1990).  Notably, corticosterone has been reported to increase CRH mRNA in
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the amygdala while not inducing it in the hypothalamus (Makino, et al., 1994; Makino, et
al., 1995).  The effects of nicotine induced corticosterone at chronic levels have not been
documented.     
Manifestations of nicotine
Nicotine 
Nicotine (1-methyl-2-(3-pyridyl) pyrolidine) is a poisonous, volatile alkaloid
derived from tobacco and is responsible for many of the tobacco effects (McDonough,
1994).  Nicotine has a pKa of 7.9 and at blood pH (7.4) is approximately 69% ionized and
31% unionized, making it more lipid soluble (Beckett, et al., 1972; Jones, 1987).  Nicotine
therefore crosses the blood brain barrier, and is a psychostimulant acting on neuronal
nicotinic receptors located in various brain regions.  In small doses, nicotine stimulates the
CNS (Armitage, et al., 1969; Gray, et al., 1996;  Nordberg, et al., 1989; Rowell, 1995),
while large doses depress the nervous system at autonomic ganglia and myoneuronal
junctions (Benwell and Balfour, 1982; Benwell and Balfour, 1985; Sharp, et al., 1993). 
Nicotine Pharmacokinetics
Nicotine has been reported to accumulate rapidly in the brain after intravenous
injections, within five minutes, and high levels last up to 50 minutes (Sastry, et al., 1995;
Schmiterlöw, et al., 1967).  In the 1967 review, Schmiterlow, et al., reported the fate of 14C
and 3H labeled nicotine in rat, mouse and cat, on studies that used autoradiographic
methods.   Nicotine was reported to accumulate rapidly in the brain, within five minutes
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peaking at about 15 minutes and decreasing by 30 minutes.  (Sastry, et al., 1995) studied
the distribution and retention of nicotine and its metabolite, cotinine, in rat plasma and
brain homogenates after intravenous administration of a 1.0 mg/kg dose.  Using high
performance liquid chromatography (HPLC) for nicotine measurements, the researchers
reported that nicotine peaked in plasma after 5-10 minutes to 2.2 nmol/ml.  They observed
a 50% decrease (in plasma levels) by 20 minutes which remained constant up to 60
minutes.  Within 20 minutes, plasma cotinine levels had peaked to 1.2 nmol/ml, with
levels remaining similar to nicotine levels for up to 60 minutes.  In the brain, nicotine
peaked within five minutes of treatment, remaining constant for 20 minutes with a decline
by 60 minutes.  The peak levels of nicotine in the brain were about half of plasma levels. 
The brain retained more nicotine compared to other organs including the heart, liver,
kidney and plasma, this possibly due to the fact that the brain has a higher density of
nicotinic receptors which would bind nicotine with high affinity (Sastry, et al., 1995).  
Isaac and Rand, (1972), collected blood samples in humans from 0.5-60 minutes
after a single cigarette.  The researchers measured plasma levels of nicotine using gas-
liquid chromatography and reported that plasma levels increased within two minutes of
smoking and peaked to 50 ng/ml by five minutes, and then decreased to half of the peak by
20 minutes.  Nicotine is metabolized by liver and kidney and its biological half life is
about 0.5, 0.6 and 0.96 hour in humans, dogs and rats respectively (Adir, et al., 1976;
Castro, 1979; Isaac and Rand, 1972; Monji and Benowitz, et al., 1988).  The resultant
metabolite cotinine has a half life of 19-24 hours and remains constant in all the organs,
meaning that it has a longer retention time (Sastry, et al., 1995).
30
Neuronal Nicotinic receptors
The neuronal acetylcholine nicotinic receptor (nAChR) is a ligand-gated ion
channel permeable to sodium (Na+), potassium (K+), and calcium (Ca2+), and therefore
participates in  neurotransmission (McGehee and Role, 1995; McGehee and Role, 1996;
Schwartz and Kandel, 1991).  The neuronal nAChR, is the primary receptor for
acetylcholine in neurons and is found in sympathetic and parasympathetic ganglia, and the
adrenal cortex (Mycek, et al., 1992).  Molecular biology, immunocytochemistry and in situ
hybridization techniques have demonstrated that  nAChRs consist of a family of
heterogeneous receptor subtypes composed of - and - subunits encoded by 12 different
genes (Luetje and Patrick, 1991; Lukas, 1995; Wada, et al., 1989).  The formation of
nicotinic receptors with heterogeneous subunit stoichemistry gives rise to multiple channel
properties and therefore, receptor types (Balfour and Fagerström, 1996; Cooper, et al.,
1991; Luetje and Patrick, 1991; Wada, et al., 1989; ). 
Eight alpha (2-9) and four beta (2-5) subunits have been identified in rat
(Benwell and Balfour, 1982; McGehee and Role, 1995; Steinbach and Ifune, 1989; Vidal,
1996).  The neuronal type nicotinic receptors include  2-5 and 2-4 (Fu, et al., 1997; Fu,
et al., 1998).  While the 2-4 subunits are widely distributed in the brain, the 2, 3, and
4 subunits are expressed only in distinct brain areas (Shioda, et al., 1997; Wada, et al.,
1989).   Molecular biology studies using Xenopus oocytes to express genes coding for the
nicotinic receptors have shown that when the oocytes were injected with mRNA or cDNA
of 2, 3, or 4 combined with 2 or 4, the receptors became functional and responded
to acetylcholine or nicotine stimulation, by exhibiting depolarizations (Bertrand, et al.,
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1990).  The alpha subunit is the agonist binding site and the beta subunit influences the
affinity and response of the receptor to the agonists (Luetje and Patrick, 1991; Lukas,
1995; Wada, et al., 1989).
In situ hybridization techniques have shown that different combinations of -and
- subunits exist in various brain regions (Papke, et al., 1989; Wada, et al., 1989).  The
42 receptor is widely distributed in the brain, while other subunit combinations are
restricted to specific areas (Clarke, et al., 1984; Flores, et al., 1991; Flores, et al., 1997).  
For example, the 22 is found in the interpeduncular nucleus, 34 in the medial
habenula (Wada, et al., 1989).  The 7 subunit which is mainly expressed in muscular
AChRs, is expressed only in the hippocampus and hypothalamus (Bylund and Yamamura,
1990; Clarke, et al., 1985; Seguela, et al., 1993).  The 42 receptor is sensitive to
nicotine, acetylcholine, and other agonists including lobeline, epibatidine, cytisine and
ABT418, but not sensitive to -bungarotoxin, the snake venom (Bylund and Yamamura,
1990; Flores, et al., 1997; Watson, et al., 1987).  Alpha bungarotoxin selectively binds to
the 7 subunit (Bylund and Yamamura, 1990; Watson, et al., 1987).  
Nicotinic receptors are believed to exist in two inter convertible states; ground and
refractory (Bhat, et al., 1994; Colquhoun, et al., 1987; McGehee and Role, 1996).  The
ground state of the receptor is activated by binding of agonists whereas the refractory is the
desensitized state and is non functional (McGehee and Role, 1996; Bhat, et al., 1994). 
High or chronic doses of nicotine desensitize the receptors and an up-regulation of
receptors ensues, to compensate for the non functional receptors (Flores, et al., 1997;
Rowell and Li, 1997; Schwartz and Kellar, 1985; Ulrich, et al., 1997).  Benwell, et al.,
32
(1988) reported an increase in density of nicotinic receptor binding sites in post mortem
brains of  smokers, suggesting that over-exposure to nicotine may have induced this
increase.  It also has been reported that the up-regulated receptors, like the desensitized,
are not active and therefore can not be associated with behavioral effects of nicotine
(Caggiula, et al., 1993; Collins, et al., 1990; Pauly, et al., 1992; Rowell and Li, 1997).  In
addition to exciting neurons in the brain, effects of nicotine are also enhanced by its
metabolites mainly cotinine, which also remain active on the nAChRs (Crooks and
Dwoskin, 1997; Sharp, et al., 1993).    
Autoradiographic techniques and immunocytochemistry have demonstrated the
existence of neuronal nicotinic receptors (nAChRs) in various brain regions, particularly in
the cerebral cortex and hippocampus (Clarke, et al., 1984; Rubboli, et al., 1994).  The
presence of nicotinic receptors and choline acetyl transferase, the acetylcholine (ACh)
synthetic enzyme, has been reported in the amygdala (Hellendall, et al., 1986; Van der
Zee, et al., 1997; Yajeya, et al., 1997).  Electrophysiological data suggest that nAChRs  are
located in both the somatodendritic membrane and in the nerve terminal (Clarke and Pert,
1985; Vidal, 1996).  This makes the receptor mediate neural activity in two ways.  At the
nerve terminal, the nicotinic receptor influences neurotransmitter secretion on target
neurons; at dendrites, the receptor mediates changes in rate and pattern of firing.  Both
mechanisms are believed to be present in the brain (Balfour and Fagerström, 1996; Vidal,
1996).  In presynaptic terminals for example, low doses of nicotine activate nAChRs on
synaptic terminals to evoke an influx of Ca2+ which in turn enhances exocytosis of  a
neurotransmitter, for example, glutamate (McGehee and Role, 1996).  
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Biochemical studies on synaptosome have demonstrated that nicotine
administration triggers the release of neurotransmitters including ACh, GABA,
norepinephrine, epinephrine, dopamine, serotonin, aspartate and glutamate, therefore
confirming the presence of presynaptic nAChRs, (Armitage, et al., 1969; Balfour and
Fagerström, 1996; Rapier, et al., 1988; Rowell and Hillebrand, 1994; Toth, et al., 1992;
Valentine, et al., 1996).  As discussed earlier, CRF neuronal systems are colocalized with
those of other neurotransmitters, which are influenced by nicotine (Fallon and Ciofi, 1992;
Okuda, et al., 1993; Shinohara, et al., 1988; Van Bockstaele, et al., 1996).  Since nicotine
influences neuronal systems  that colocalize with CRF systems (Okuda, et al., 1993), this
suggests that nicotine could also have an influence on the CRF.  
Nicotine and HPA axis
Nicotine administration into rats increases plasma ACTH and corticosterone levels
(Benwell and Balfour, 1979; Cam and Bassett, 1983; Freund, et al., 1988). 
Catecholamines are reported to play a role in triggering CRF release in the PVN of
hypothalamus for the ultimate release of ACTH in the anterior pituitary (Andersson, et al.,
1983; Matta, et al., 1993b).  Nicotine stimulates c-fos immunoreactivity in the CeA, PVN
and brain stem catecholaminergic regions (Matta, et al., 1993a; Matta, et al., 1997;
Salminen, et al., 1996).  This suggests that nicotine is a potent activator of neuronal
activity in catecholaminergic and CRF regions.  It has been reported that CRF receptors
are possibly colocalized with nAChRs in the median eminence (Okuda, et al., 1993)
suggesting that nicotine may modulate CRF release at median eminence.  Majewska, et al.,
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(1985) reported that glucocorticoids also induced muscimol binding in the GABA
receptors which are possibly colocalized with nicotinic and CRF receptors.  Together this
and other studies further confirm the inhibitory effects contributed by glucocorticoids on
CRF receptors and possibly on nicotinic receptors (Johnson, et al., 1995; Sapolsky, et al.,
1990).
Nicotine and the amygdala
The amygdala has considerable levels of CRF, cholinergic projections from basal
forebrain  (Heckers and Mesulam, 1994) and also expresses nicotinic receptor
immunoreactivity, and choline acetyl transferase, the acetylcholine synthetic enzyme
(Hellendall, et al., 1986).  Cholinergic fibers from basal forebrain reach the amygdala
through the stria terminalis and the amygdalofugal pathway (Heckers and Mesulam,
1994).  Roozendaal, et al., (1997), reported that in amygdala, 90% of the cholinergic
afferents expressed nicotinic receptor immunoreactivity, and as seen in the neocortex,
muscarinic and nicotinic receptors are colocalized in amygdala (Van der Zee, et al., 1992;
Van der Zee, et al., 1997).  Electrophysiological techniques by Yajeya, et al., (1997),
showed that most of the amygdaloid neurons responded to carbachol which is an agonist
at both nicotinic and muscarinic receptors.  A more specific nicotinic agonist would be
necessary to help determine nicotinic receptor responses in the amygdala.  Microdialysis
techniques showed that administration of nicotine into the amygdala induced NE release
in brain stem catecholaminergic regions (Fu, et al., 1997; Fu, et al., 1998).  Raber, et al.,
(1995), studied primary cultures and reported that CRF release in the amygdala was
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influenced by interleukin, ACh and norepinephrine.  A 1997 study by Matta, et al.,
reported increased c-fos expression in CRF immunoreactive neurons after nicotine
administration.    
Nicotine and neurotransmitters
Acetylcholine secretion 
Acetylcholine (ACh) is an excitatory neurotransmitter, its secretion in the brain is
strongly associated with locomotor activity and cognitive stimulation (Armitage, et al.,
1969; Balfour and Fagerström, 1996; Warburton and Rusted, 1993).  Nicotine has been
shown to modulate locomotor activity in animals and this is mediated through activation
of ACh secretion resulting in muscarinic activation (Armitage, et al., 1969; Levin, 1992). 
There are variations in responses elicited by different dosing times, regimens and routes
of administration of nicotine.  However, Armitage, et al., 1968 showed that high doses of
nicotine suppressed ACh release, and could be demonstrated by decreased locomotion,
due to desensitization of the nicotinic receptor (Armitage, et al., 1968; Armitage, et al.,
1969; Hakan and Ksir, 1991).  This is to be expected because nicotine is a stimulant at
low doses and depressant at high doses (Benwell and Balfour, 1982; Gray, et al., 1996;
Sharp, et al., 1993). 
Role in nicotine rewarding properties.  It is believed that smokers use tobacco for
nicotine to modulate level of arousal, attention or sustained concentration and cognitive
performance (Acri, et al., 1994; Balfour and Fagerström, 1996; Warburton, 1992).  The
need to satisfy this CNS effect is believed to modulate the desire to smoke.  It has been
36
reported that one of the ways nicotine elicits these CNS effects is through stimulation of
the ACh secretion in the brain, particularly the hippocampus (Levin, 1992; Armitage, et
al., 1968; Armitage, et al., 1969). 
Pharmacological disruption of cholinergic neurotransmission or neurodegeneration
cause impairments in cognitive skills (Balfour and Fagerström, 1996; Levin, 1992; Levin,
et al., 1992).  For example, Alzheimer's and Parkinson's diseases are characterized by a
loss of cortical nAChRs and patients show an improvement in memory and attention after
nicotine treatment (Balfour and Fagerström, 1996; Kellar, et al., 1987; Levin, 1992; Vidal,
1996).  Two reviews by Warburton, (1992) and Warburton and Rusted, (1993) surmised
that tobacco smoking or administration of nicotine elicited cognitive-enhancing effects,
more related to information processing, as observed in Alzheimer’s patients treated with
nicotine.   In monkeys, ABT418, an agonist at nAChRs, improved accuracy in learning
and memory (Prendergast, et al., 1997).  
 
Norepinephrine secretion
Nicotine has been reported to excite noradrenergic neurons in the brain stem (Fu,
et al., 1997; Fu, et al., 1998; Sharp and Matta, 1993).  Noradrenergic innervation arises
from the locus coeruleus, nucleus tractus solitarius and neurons of the reticular formation
(Gray, 1993; Haines, 1991).  The noradrenergic system innervates mainly the cortical,
subcortical and spino medullary regions and PVN (Haines, 1991).  Norepinephrine plays a
vital role in memory and learning, sleep-wake cycle and affective disorders (Bremner, et
al., 1996).  Svensson and Engberg, (1980) used single cell recording techniques and
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demonstrated that noradrenergic neurons express nicotinic receptors on both
somatodendritic membranes in the LC and the nerve terminal membranes.  Egan and
North, (1986), used LC slices to demonstrate that nicotine and ACh depolarize LC
neurons, indicating the presence of nAChRs.  This and other studies suggest that nicotine
plays a part in exciting the NE neurons in brain stem (Benwell and Balfour, 1997; Fu, et
al., 1997; Fu, et al., 1998; Sharp and Matta, 1993).
In vivo microdialysis studies performed by Andersson, et al., (1981), and Mitchell,
(1993), showed that nicotine administration increased NE turnover in the rodent brain. 
This was further confirmed in immunocytochemical studies (Valentine, et al., 1996) which
showed that an increase in c-fos immunonoreactivity in PVN correlated with c-fos in
nucleus tractus solitarius.  Studies on hypothalamic synaptosomes revealed that low
concentrations of nicotine (5 x 10-6 M) caused an increase in NE release (Balfour, 1973;
Yoshida, et al., 1980).  Acute administration of 100 M nicotine increased NE in fetal LC
cell cultures (Gallardo and Leslie, 1998).  Nicotine also induces NE release from nucleus
tractus solitarius and LC which project to the PVN and  contribute to NE release for
ultimate stimulation of CRF release in PVN (Gray and Bingaman, 1996).  A recent study
by Fu, et al., (1998) using microdialysis techniques showed nicotine to induce NE release
in amygdala and hippocampus.  All these effects were inhibited by mecamylamine, a
centrally acting noncompetitive antagonist of nicotine (Morgan and Pfeil, 1979).  A
decrease in NE in the amygdala has been associated with an increase in hypothalamic
activity  (Goldstein, et al., 1996), suggesting a role of amygdala in activation of the
hypothalamus. 
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In addition to its brain stem effects, nicotine also modulates NE levels in other
brain regions.  However, brain regions including the hippocampus, cerebral cortex, and
cerebellum, require high concentrations of nicotine to cause an increase in NE turnover
(Smith, et al., 1991).  Sershen, et al., (1997) studied hippocampal slices and reported that
32 receptor controlled NE release in the slices.  Three studies have reported that chronic
nicotine injections seem to exert selective sensitization of hippocampal NE release and
turnover probably due to increased synthesis of tyrosine hydroxylase, the rate limiting
enzyme in the synthesis of NE (Joseph, et al., 1990; Mitchell, 1993; Smith, et al., 1991). 
However, subcutaneous minipump infusion of nicotine elicited contrasting results.  Kirch,
et al., (1987), reported that minipump infusions of nicotine lowered NE levels in the
frontal cortex,  possibly abolishing NE overflow in the hippocampus (Balfour and
Fagerström, 1996).  These findings suggest that NE secreting neurons located in the
hippocampus originating from the LC get desensitized by chronic exposure to nicotine
levels that are comparable to the 10-25 ng/ml found in habitual smokers (Armitage, et al.,
1968; Balfour and Fagerström, 1996; Isaac and Rand, 1972).  Therefore, nicotine
influences both cholinergic and catecholaminergic systems that play a role in the
interrelationships between hypothalamus, amygdala and brain stem (Fu, et al., 1997; Fu, et
al., 1998; Levin, et al., 1992; Matta, et al., 1993b; Valentine, et al., 1996).
Role in nicotine dependence. The hippocampus plays a role in nicotine
dependence (Markou, et al., 1998; Mitchell, 1993; Smith, et al., 1991).  Chronic infusions
of nicotine using minipumps desensitize nicotinic receptors and decrease NE release in
neurons which innervate the hippocampus, originating from the LC (Balfour and
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Fagerström, 1996; Smith, et al., 1991).  This desensitization of receptors and reduction in
NE is believed to play a critical role in mediating the "calming" effects of tobacco (Gilbert,
et al., 1997; Pomerleau and Pomerleau, 1987).  This therefore, suggests that smokers seek
to smoke in order to maintain desensitized nicotinic receptors and that an individual would
adjust the smoking behavior in order to achieve this effect (Benowitz and Jacob, III, 1997). 
Dopamine release
Nicotine stimulates and sensitizes dopamine neurons to increase dopamine (DA)
secretion, and nicotine also inhibits DA reuptake by neurons (Benwell and Balfour, 1992;
Izenwasser, et al., 1991; Shoaib, et al., 1994).  DA is abundant in the brain, mainly found
in the basal ganglia particularly the caudate nucleus (Carlsson and Waldeck, 1958).  DA
secreting neurons originating from the ventral tegmental area (VTA) to the nucleus
accumbens (NAcc) and from substantia nigra (SN) to caudate/putamen (CP) have nicotinic
receptors on both the somatodendritic membranes and nerve terminal membranes (Clarke
and Pert, 1985; Corrigall, et al., 1992; Marshall, et al., 1997).  Nicotine has been reported
to increase (DA) overflow in NAcc and CP, and dopamine release increased in striatal
synaptosomes (Grady, et al., 1994; Rapier, et al., 1988; Rapier, et al., 1990; Rowell and
Hillebrand, 1994).  These researchers demonstrated that when synaptosomes derived from 
caudate putamen (CP) area or nucleus accumbens were stimulated with nicotine an
increase in DA secretion was observed.  The response was calcium dependent and
antagonized by mecamylamine, the nicotine noncompetitive antagonist.  These 
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findings confirmed that responses to nicotine are elicited through presynaptic nicotinic
receptors.  Microdialysis probes into the NAcc also demonstrated increased DA overflow
after nicotine treatment (Mifsud, et al., 1989; Nisell, et al., 1994).  Microdialysis
techniques have shown that DA overflow in the NAcc increases due to systemic nicotine
injections and this overflow mediated mainly by nicotinic receptors located in the
somatodendritic membranes in the VTA (Bassareo, et al., 1996; Benwell and Balfour,
1992; Marshall, et al., 1997).  
Studies by Imperato, et al., (1986) and Mereu, et al., (1987), suggested that,
compared to nigrostriatal system, mesolimbic neurons are more sensitive to nicotine. 
Garris and Wightman, (1994), used microdialysis and voltametric probes and which
indicated that DA flow in the both CP and NAcc synaptic clefts is tightly controlled by a
transport system which is more efficient in the CP, which would partly explain the
differences in the sensitivity to nicotine.  Unlike the desensitization effects observed in the
ACh, NE and 5-HT systems, repeated injections of nicotine enhance DA overflow in the
NAcc (Benwell and Balfour, 1992; Pietilä, et al., 1996), but this was contrasted by a study
that demonstrated a decrease in dopamine release in synaptosomes after repeated nicotine
doses (Grady, et al., 1994).  Sensitization of the mesolimbic DA system is modulated
through the nicotinic receptor since it is attenuated by prior administration of
mecamylamine.   It has also been reported that sensitization of these DA receptors depends
on the co-stimulation of the NMDA receptor since this sensitization is diminished by prior
treatment with NMDA receptor antagonists (Shoaib, et al., 1994; Shoaib, et al., 1997). 
This sensitization of DA neurons, reinforces the belief that DA systems mediate
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behavioral responses to nicotine, particularly, locomotor stimulation and rewarding
properties of the drug (Clarke and Pert, 1985;  Corrigall and Coen, 1989; Corrigall, et al.,
1992).  
Role in nicotine dependence.  Existing studies on experimental models of
depression (stress) indicate that behavioral activation is dependent on the enhanced
secretion of dopamine (DA) in mesoaccumbens system, and the system is a critical
component of the reward system that influences reinforcement (Benwell and Balfour,
1992; Gray and Bingaman, 1996).   Piccioto, et al., (1998) reported stimulation of
dopamine release by nicotine in ventral striatum of wild type mice compared to 2 subunit
mutant mice.  These researchers concluded that striatal nAchRs containing the 2 subunit
are involved in the reinforcing properties of nicotine.  This as discussed earlier, suggests
the involvement of the nicotine sensitive 42 receptor (Flores, et al., 1991). 
Dopamine neurons are sensitized by high or chronic levels of nicotine to increase
DA secretion, and nicotine also inhibits DA reuptake thus enhancing the availability of
DA (Benwell and Balfour, 1992; Izenwasser, et al., 1991; Shoaib, et al., 1994;).  This
would suggest that in chronic doses, as nicotine receptors get desensitized, the capability
to activate dopamine neurons is compromised thus eliciting a need for more nicotine,
which eventually leads to negative effects.  Researchers report that experimental animals
need a “time out” from nicotine self administration because the presence of nicotine with
receptors desensitized, becomes aversive.  Time off reduces drug levels and minimizes
receptor desensitization (Balfour and Fagerström, 1996).   Possibly, smokers seek smoke
to replenish nicotine levels, overcome desensititized receptors, and recruit non-
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desensitized receptors to trigger neurotransmission and therefore increase dopamine
release, thus contributing to the “calming” effects of nicotine (Gilbert, et al., 1997;
Pomerleau and Pomerleau, 1987). 
5-hydroxytryptamine (serotonin) secretion
Nicotine has been shown to decrease serotonin in selected regions of the
mammalian brain while decreasing the neurotransmitter in others (Balfour, et al., 1975;
Bannon, et al., 1998; Benwell and Balfour, 1979).  The mammalian forebrain gets its
serotonergic innervation from the  median and dorsal raphe nuclei located in the brain
stem (pons and medulla) (Haines, 1991).  These nuclei express a significant amount of the
4 subunit of the nicotinic receptor (Wada, et al., 1989).  Other brain areas with
considerable amounts of 5-hydroxytryptamine (5-HT) include the hypothalamus, limbic
system and pituitary gland (Benwell and Balfour, 1979).  
Serotonin is believed to modulate a number of behavioral aspects, including pain
perception, sleep, depression, anxiety, mood changes and sexual activity and acts through
different receptors including 5-HT1, 5-HT2,  5-HT3, 5-HT4 (Kidd, et al., 1993).  
Antidepressants are used to modulate serotonin levels or antagonize receptors (Charney, et
al., 1990; Graeff, et al., 1996; Kandel, 1991; Kidd, et al., 1993).  The 5-HT1a receptor plays
a role in fear conditioning in the amygdala while 5-HT2 mediates mood states (Charney, et
al., 1990; Fernandes, et al., 1997; Graeff, et al., 1996).  The 5-HT3 receptor is found in
high densities in the brain and is significantly localized in nerve terminals of amygdala
where it evokes fast excitatory transmission (Kidd, et al., 1993; Sugita, et al., 
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1992).  Kawahara et al., (1993), reported that psychological stress increases serotonin in
the amygdala, and 5-HT3 antagonists have been shown to be anxiolytic in animal models
of behavior (Charney, et al., 1990; Graeff, et al., 1996). 
Nicotine has been shown to decrease serotonin in selected regions of the
mammalian brain, this may be possibly because of  increased metabolism of the
neurotransmitter caused by nicotine (Bannon, et al., 1998).  Nicotine decreases serotonin
in the hippocampus, but increases this neurotransmitter in the amygdala (Balfour, et al.,
1975; Benwell and Balfour, 1979).  Balfour, et al., (1975), demonstrated that acute
injections of nicotine in normal rats cause a transitory decrease in hippocampal serotonin,
decreases were observed within 45 minutes, with a rise occurring by 60 minutes.  In
stressed rats, acute nicotine caused a persistent reduction in serotonin for up to 75 minutes
(Balfour, et al., 1975).  Chronic infusion of 0.4 mg/kg for 40 days evoked a more stable,
persistent, regionally selective decrease in hippocampal serotonin, resulting from selective
reduction in the biosynthesis of serotonin (Benwell and Balfour, 1982).  A regional
reduction in serotonin and the metabolite 5-hydroxyindole acetic acid, and an up-
regulation of serotonin receptors, like nAChRs,  has  been observed in postmortem tissue
of habitual smokers (Benwell, et al., 1988; Benwell, et al., 1990).  This supports the notion
that this system may play a role in the psychopharmacological response to nicotine and its
contribution to the habit of tobacco smoking (Balfour and Fagerström, 1996).
Role in nicotine dependence.   Nicotine withdrawal is strongly associated with
symptoms of depression, while nicotine dependence has been associated with a history of
depression (Breslau, et al., 1993; West and Hajek, 1997).  Rasmussen, (1997) studied
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effects of nicotine withdrawal on serotonergic neurons in rat nucleus raphe, using 5HTIA 
receptor agonist 8-OH-DPAT.  They reported that nicotine withdrawal increased
sensitivity to the auditory startle response, indicating sensitivity to external stimuli.  In a
similar study, Rasmussen, et al., (1997) reported that 5HTIA antagonists blocked the startle
response that is enhanced by nicotine withdrawal.  These researchers concluded that the
serotonergic system is possibly associated with symptoms of nicotine withdrawal.   A
study by Hurt, et al, (1997), tested the antidepressant bupropion (which possibly functions
on both serotonergic and noradrenergic receptors) for smoking cessation in a study that
involved 615 subjects.  The researchers reported that compared to placebo, more smokers
who received the sustained-release form of bupropion were able to stay smoke free for the
duration of the (one year) tested time.  This suggested that the antidepressive effects of
bupropion enabled subjects to have a decreased need for nicotine.  However, neural
mechanisms underlying the antidepressive properties of nicotine have yet to be elucidated. 
 
Nicotine and the NMDA receptor   
The NMDA receptor is involved in responses to chronic nicotine (Shoaib and
Stolerman, 1992; Shoaib, et al., 1994; Shoaib, et al., 1997).  The NMDA receptor plays an
important role in  long term potentiation in the amygdala and nicotine has stimulatory
effects on glutamate release (McGehee and Role, 1996; Toth, et al., 1992).  In pyramidal
cells of the prefrontal cortex, excitatory synaptic potentials mediated by glutamate are
potentiated by nicotine (Vidal, 1996; Vidal and Changeux, 1993).  Since glutamate plays a
role in synaptic plasticity, the enhancement of glutamatergic terminals by nicotine in the
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prefrontal cortex further explains the role of nicotine in learning and memory (Shoaib, et
al., 1994; Shoaib, et al., 1997).  These studies point to functional cooperation between
nicotinic and glutamatergic systems in the cortex which would 
represent a unified involvement of the two systems in cognitive processes (Toth, et al.,
1992; Vidal, 1996). 
Positive reinforcing properties of nicotine
The effects of nicotine on animal behavior are impacted by several factors
including dose, route of administration, species and strain, prior exposure to the drug and
nature of test used (Balfour and Fagerström, 1996; Donny, et al., 1998).  Similar to
psychostimulants like amphetamine and cocaine, the effects of acute nicotine on animals
are manifested by locomotor stimulation (Hakan and Ksir, 1991; Mifsud, et al., 1989). 
Acute high doses or chronic low doses decrease locomotor stimulation due to receptor
desensitization Ksir, et al., (1987) and also because high doses decrease ACh release
(Armitage, et al., 1968).  Positive reinforcing properties (rewarding properties) of
addictive drugs are manifested in the animal's self administration of the drug as measured
using the self administration paradigm (Balfour, 1982; Balfour and Fagerström, 1996;
Donny, et al., 1998).  With amphetamine and cocaine, both the acquisition and
maintenance of drug usage behavior have been shown to depend on an intact DA system
(Glick, et al., 1996), that is, DA projections to the NAcc, where a large increase in DA
overflow is observed after drug treatment (Benwell and Balfour, 1992; Izenwasser, et al.,
1991; Shoaib, et al., 1994).  
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Maintenance of nicotine self administration also involves DA neurons that project
from the VTA, but the paradigm is not easy to demonstrate in animals, because nicotine
has weaker reinforcing properties compared to cocaine and amphetamine (Corrigall and
Coen, 1989; Corrigall, et al., 1992; Corrigall, et al., 1994).  In a study by Dawe, et al.,
(1995), on humans who were initially treated with haloperidol, a DA receptor antagonist,
individuals were found to increase their smoking to overcome this blockade and once
achieved they maintained the new dose of smoke, with satisfaction.  In the self
administration paradigm, the response for nicotine is reported to be bell shaped, with
higher doses possibly becoming aversive rather than rewarding 
(Balfour, 1982; Balfour and Fagerström, 1996; Hildebrand, et al., 1997; Rose and
Corrigall, 1997; Valentine, et al., 1997).  CRF has also been implicated to play a role in
drug seeking behaviors in that intracerebroventricular injections of CRF to stressed
animals induced a relapse to cocaine seeking, an effect that was attenuated by the presence
of  the antagonist, -helical CRF and d-phe CRF (Heinrichs, et al., 1998).   
Nicotine and neurological diseases
As discussed earlier, animal and human studies on nicotinic receptors suggest that
neuronal nicotinic systems play a major role in cognitive functions and dysfunctions
(Balfour and Fagerström, 1996; Clarke and Pert, 1985; Levin, 1992).  Nicotine and
analogues seem to influence brain neural systems that are implicated in psychiatric and
neural disorders (Balfour and Fagerström, 1996; Roozendaal, et al., 1997; West and Hajek,
1997).  Regionally selective losses of the nicotinic receptors that bind [3H](-)-nicotine and
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[3H]-ACh are associated with cognitive impairments observed in diseases like Alzheimer’s
(AD) which affects memory and Parkinson’s (PD) which affects mobility (Flynn and
Mash, 1986; Jones, et al., 1992; Nordberg, et al., 1989).  Nicotine therefore, could be used
therapeutically to treat these diseases (Levin, 1992).  For example, Alzheimer's and
Parkinson's diseases are characterized by a loss of cortical nAChRs and patients show an
improvement in memory and attention after nicotine treatment (Kellar, et al., 1987; Levin,
1992; Vidal, 1996).  CRF is also decreased in AD and PD, suggesting a possible
interaction between nicotine and CRF in the etiology of these pathologies 
(De Souza, 1995; De Souza, et al., 1985).  
Is nicotine anxiolytic?
Smokers report that after exposure to stressful stimuli smoking has a calming
effect   (Benowitz and Jacob, III, 1997; Gilbert, et al., 1997; Pomerleau and Pomerleau,
1987).  This  is a paradox because nicotine elicits effects that resemble stressful stimuli,
for example, increased norepinephrine secretion and circulating ACTH and corticosterone
(Benwell and Balfour, 1982; Cam and Bassett, 1983; Jones, 1987).  It should be noted that
having a cigarette in the hand, something to pay attention to, may contribute to the
alleviation of anxiety symptoms (Jones, 1987; West and Hajek, 1997).  The role of
nicotine as an anxiolytic has been observed using animal models of anxiety, including
elevated plus maze, sensory motor gating and nicotine ingestion when exposed to stress
(Acri, et al., 1994; Brioni, et al., 1993; Brioni, et al., 1994).  Rats treated with nicotine
(0.01 to 1.0 mg/kg) were reported to spend more active time in the illuminated area than 
48
in the dark implying that animals were less fearful (Costall, et al., 1989).  Neural
mechanisms in the reinforcing properties of nicotine are possibly different from those of
anxiolytic properties of nicotine in that they depend on desensitization of the nicotinic
receptors located on synapses of pathways that mediate the stress response, for example
CRF and NE (Balfour and Fagerström, 1996; Benwell and Balfour, 1997).  Whether or not
the apparent anxiolytic effects of nicotine may be similar to those evoked by
antidepressants rather than anxiolytic drugs have yet to be investigated convincingly
(Balfour and Fagerström, 1996).  
A few researchers have examined effects of nicotine withdrawal using animal
models of anxiety and it is still debatable whether or not nicotine or withdrawal from
nicotine increases anxiety (Helton, et al., 1993; Jones, 1987; Rasmussen, et al., 1997; West
and Hajek, 1997).  Helton, et al., (1993), reported that nicotine withdrawal increased
sensory motor reactivity suggesting a manifestation of anxiogenic effects.  Studies by
Costal, et al., (1989); Crooks and Dwoskin, (1997) used the light/dark box paradigm on
mice and found that nicotine withdrawal caused an increase in anxiety.  This anxiety was
diminished by the antidepressant diazepam and by the 5-HT3 receptor antagonist,
ondasteron, indicating an interrelationship between GABAergic and serotonergic with
cholinergic synapses (Costall, et al., 1989; Crooks and Dwoskin, 1997; Rasmussen, et al.,
1997).   
Smoking or self administration of nicotine by animals may be a way to seek a
coping mechanism against aversive environmental stimuli (Balfour, 1982).  A potent
nicotinic receptor agonist ABT 418 was studied by (Sajdyk and Shekhar, 1997).  The
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researchers found that 0.062- 30 mol/kg of ABT 418 caused anxiolytic effects in rats, as
shown by increased activity in the elevated plus maze, effects that were also produced by
nicotine.  Kumari, et al., (1996), reported a decrease in prepulse inhibition of the acoustic
startle suggesting an increase in the ability to screen irrelevant sensory stimuli, that is,
increased attention.  Anhedonic properties of aversive environmental stimuli can be
depressive or anxiogenic and for individuals who have been exposed to smoking, this
triggers the desire to smoke (Balfour, 1982; Jones, 1987).  To further support the
antidepressive properties of nicotine, a smoking cessation study by Hurt, et al, (1997),
reported that compared to placebo, more smokers who received the sustained-release form
of bupropion were able to stay smoke free for the duration of the (one year) tested time. 
These findings could suggest that in humans, the ability of nicotine to alleviate stress is a
quality that enables this drug to reinforce its self-administration (Balfour and Fagerström,
1996; Jones, 1987).  If nicotine is anxiolytic or antidepressive, we should expect that both
doses 0.4 mg/kg and 1.0 mg/kg which give rat levels equivalent to 10-40 ng/ml)
maintained by regular smokers (Balfour and Fagerström, 1996; Isaac and Rand, 1972)
would decrease CRF content in amygdala and hypothalamus.
Is nicotine anxiogenic? 
Anxiogenic responses can be measured using animal models of anxiety, including
mazes and/or the acoustic startle responses.  As discussed earlier, CRF has been reported
to induce defensive withdrawal symptoms in mazes and potentiate acoustic startle
responses.  Acri, et al.,  (1993) and (1994),  used very high doses (6 and 12 mg/kg) of
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nicotine and the acoustic startle paradigm.  The 6 mg/kg/day dose gives rat levels
equivalent to (40-80 ng/ml) those of a human smoking 3 packs of 20 cigarettes per day
(Isaac and Rand, 1972).  The researchers found that nicotine treated animals had increased
acoustic startle responses compared to untreated.  The studies indicated that nicotine
treated rats had increased attention processes, as expected, but this also suggested
anxiogenic effects of nicotine.  
The researchers (Acri, 1994; Acri, et al., 1994; Kumari, et al., 1996) further
reported that nicotine elevated sensory gating as measured by prepulse inhibition of the
acoustic startle.  Like CRF, nicotine manifests anxiogenic and stress symptoms.  The
inference from these studies is that nicotine can be anxiolytic or anxiogenic, depending on
the dose and whether treatment is acute or chronic.  For the present study, if nicotine is
anxiogenic, we should expect that acute doses of  0.4 mg/kg or 1.0 mg/kg which give rat
levels equivalent to the 10-40 ng/ml maintained by regular smokers (Balfour and
Fagerström, 1996; Isaac and Rand, 1972), would elavate CRF content in the amygdala and
hypothalamus.
Nicotine and corticosterone
Acute and chronic nicotine have been shown induce increased plasma ACTH and
corticosterone levels (Benwell and Balfour, 1979; Benwell and Balfour, 1982; Cam and
Bassett, 1983; Freund, et al., 1988).  The increase is dose dependent and is observed
within 15 minutes and persists for up to 60 minutes after acute treatment and up to two
weeks after chronic treatment (Benwell and Balfour, 1979; Benwell and Balfour, 1982;
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Cam and Bassett, 1983; Freund, et al., 1988; Pauly, et al., 1990).  Corticosterone and its
metabolites have been reported to decrease excitability in the nervous system and this
effect is through the modulation of the GABA receptor (Harrison and Simmonds, 1984;
Kendall, et al., 1982; Majewska, et al., 1985) and nicotine has been reported to modulate
glutamate activity on the NMDA receptor (Vidal and Changeux, 1993).  Caggiula, et al.,
(1993), reported increased tail flick latencies in nicotine treated rats with intact adrenals
compared to adrenalectomized and stressed rats, thus confirming the nociceptive effects of
nicotine and possibly enhancement by corticosterone.  The observations led Caggiula, et
al., (1993); Caggiula, et al., (1998) and  Pauly, et al., (1988) to conclude that the increase
in corticosterone after nicotine treatment is a way for neuronal systems to cope with the
effects of nicotine. 
Nicotine also manifests an increase in corticosterone through the its peripheral
effects on the adrenal cortex, an effect that was reported by (Bugaski, et al., 1998).  In
conjunction with studying effects of indomethacin (a cyclooxygynase inhibitor) regarding
nicotine-induced effects on ACTH and corticosterone levels, the researchers confirmed
inhibitory effects of hexamethonium, a peripheral nicotinic receptor inhibitor, on
corticosterone synthesis.
The increase in corticosterone by nicotine administration reflects an increase in the
activation of the HPA axis, as seen in acute and chronic stress.  Pretreatment with
corticosterone  reduces responsiveness to nicotine and effects of nicotine are manifested
differently in stressed and unstressed rats because stressed rats already have increased
levels of corticosterone (Bullock, et al., 1997; Caggiula, et al., 1993).  Balfour, et al.,
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(1975); Hall and Morrison, (1973) tested effects of nicotine on stressed and unstressed rats
and found that acute nicotine increased corticosterone in unstressed rats but had no effects
on the feedback inhibition exerted by high corticosterone levels in stressed rats.  These
effects were confirmed by the antagonistic effects of metyrapone on adrenal corticosterone
synthesis (Balfour, et al., 1975).  The findings further confirm that corticosterone has a
role in modulating the animal’s response to nicotine.
Chronic nicotine causes an up-regulation of nicotinic receptors in the brain
(Benwell, et al., 1988; Rowell and Li, 1997; Schwartz and Keller, 1983; Ulrich, et al.,
1997) and corticosterone also causes an up-regulation of nicotinic receptors (Pauly, et al.,
1990).  Corticosterone and nicotine possibly have a synegystic effect in the up-regulation
of nicotinic receptors.  The upregulated nAChRs are believed to be nonfunctional, possibly
because they are maintained at a refractory state, and thus contribute to the tolerance to
nicotine (McGehee and Role, 1996).  Behavioral and receptor binding tests on mice, by
Pauly, et al., (1992) confirmed that chronic levels of corticosterone induce tolerance to
nicotine.  These studies suggest that this tolerance may also be mediated through
corticosterone's up-regulation of nicotinic receptors (Johnson, et al., 1995; Pauly, et al.,
1990; Sapolsky, et al., 1990).  Conditioned tolerance occurs to some behavioral and
endocrine effects of nicotine (Marks, et al., 1983; Sharp and Matta, 1993).  Nicotine
administration induced a dose dependent tolerance to nicotine's effects on heart rate,
respiration rate, locomotor activity, acoustic startle responses, body temperature and
seizure threshold (Marks, et al., 1983; Marks, et al., 1985; Hakan and Ksir, 1991).  Pauly,
et al., (1988) ran behavioral tests including the Y-maze and startle response, and
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monitored heart rate and body temperature of normal and adrenalectomized rats.  The
researchers found that adrenalectomized rats, (with deficient corticosterone) exhibited
increased sensitivity to nicotine compared to non-adrenalectomized.  The researchers
concluded as mentioned above, that the increase in corticosterone is a way of coping with
nicotine’s effects.  
High concentrations of corticosterone in rats were reported to decrease CRF
receptor (CRH-R) mRNA in the PVN and BLA confirming the negative feedback
inhibition of CRF by corticosterone (Makino, et al., 1995).  In this study, Makino, et al.,
(1995), further demonstrated that chronic stress up-regulated CRF-R mRNA, indicating
that the stress input can override the feedback inhibitory effects of corticosterone to up-
regulate CRH-R mRNA in the PVN.
Nicotine versus CRF
The discussed literature suggests that nicotine and CRF could influence each other
in neuronal systems either directly or indirectly through other neurotransmitters.  In their
study of  possible involvement of interleukin-2 and nitric oxide in CRF release, Raber,  et
al., (1995), also reported that both acetylcholine and norepinephrine induced the release of
CRF from the hypothalamus and amygdala. The acetylcholine effect was antagonized by
both atropine and mecamylamine indicating the involvement of both muscarinic and
nicotinic receptors.   The norepinephrine effect was also antagonized by phentolamine and
propranolol suggesting that both  and  adrenergic receptors are involved in stimulation
of CRF release in amygdala and hypothalamus.
54
It is believed that affective disorders are influenced by changes in biogenic amine
transmission (Schwartz and Kandel, 1991).  Both nicotine and CRF influence
neurotransmitters such as norepinephrine and serotonin (5-hydroxytryptamine), suggesting
that nicotine exerts its CNS effects by influencing these systems (Calogero, et al., 1989;
Fu, et al., 1998).   Nicotine craving or nicotine withdrawal are reported to be associated
with affective disorders (Balfour and Fagerström, 1996; Fergusson, et al., 1996; Frederick,
et al., 1998) while CRF is implicated in affective disorders (De Souza, 1995; Nemeroff, et
al., 1991; Owens and Nemeroff, 1993; Owens, et al., 1991).  Indeed, behavioral models of
anxiety including social interaction, elevated plus maze and fear potentiated startle
indicate that CRF is anxiogenic (Dunn and Berridge, 1990; Liang, et al., 1992a; Liang, et
al., 1992b; Koob and Bloom, 1985).  Some of these anxiogenic reactions can also be
observed after nicotine administration (Acri, 1994; Acri, et al., 1994; Kumari, et al., 1996).
Diseases like Alzheimer’s and Parkinson’s are manifested by a decrease in CRF
levels and an up-regulation of CRF receptors, while hypersecretion of CRF results in down
regulation of receptors (De Souza, 1995; De Souza, et al., 1985; De Souza, et al., 1986;
Nemeroff, et al., 1988).   Nicotinic receptors are significantly decreased in the cerebral
cortex of patients with Alzheimer’s and Parkinson’s diseases (Jones, et al., 1992; Kellar, et
al., 1987; Vidal, 1996).  These observations, would suggest a relationship between
nicotinic receptor activation and CRF metabolism, and possibly in the etiology of these
diseases (Christensen, et al., 1992).  It is conceivable that nicotine used therapeutically for
these diseases (Jones, et al., 1992), would also improve CRF levels, but this possibility
still needs to be studied. 
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Like nicotine, CRF administration induces metabolism of brain stem
catecholamines.  CRF stimulates NE release from LC (Rivier, et al., 1984; Valentino, et
al., 1991) but nicotine also increases NE release in hypothalamus and brain stem
catecholaminergic regions (Andersson, et al., 1981; Fu, et al., 1997; Fu, et al., 1998;
Yoshida, et al., 1980).  Nicotine influences NE and has cardiovascular effects, (Grunberg,
et al., 1988; Pauly, et al., 1988), and the amygdala which is influenced by CRF and NE
also has effects on the cardiovascular system (Davis, 1992; Gray and Bingaman, 1996). 
With CRF and NE neuronal systems colocalized (Gray and Bingaman, 1996; McDonald,
1996; Van Bockstaele, et al., 1996), the question is whether or not nicotine also modulates
CRF, which in turn modulates NE or possibly nicotine influences these neurotransmitters
simultaneously.  Since NMDA and CRF receptors colocalize, CRF and glutamate
influence each other, while nicotine influences glutaminergic systems, and possibly CRF
(Gray and Bingaman, 1996). 
Both nicotine and CRF exert anorexic effects, and CRF has thermogenic effects
(Balfour and Fagerström, 1996; Le Feuvre, et al., 1991; Owens and Nemeroff, 1991;
Winders and Grunberg, 1990).  The anorexic effects of nicotine have been reported in
humans, with smokers reporting weight gain after smoking cessation (Jones, 1987).  It has
been documented that CRF suppresses food consumption and modulates gastric motility in
rats, and CRF levels have been reported to be increased in anorexic patients (De Souza,
1995; Monnikes, et al., 1992; Owens and Nemeroff, 1991).  High levels of CRF trigger
sympathetic outflow which results in hyperglycemia as a result of activated gluconeogenic
pathways, this leads to increased energy utilization and decreased body weight (Brown, et
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al., 1982; Heinrichs, et al., 1996).  The role of CRF in body weight is consistent with the
fact that the hypothalamus has a vital role in body thermoregulation and food intake (Le
Feuvre, et al., 1991; Leal and Moreira, 1996).  Animal studies have shown that nicotine
diminished feeding, increased energy utilization and therefore caused a decrease in body
weight (Grunberg, et al., 1984; Grunberg, et al., 1988; Winders and Grunberg, 1990).
Nicotine has been shown to modulate a number of neurotransmitter systems that
also interact with CRF in the rat brain, including among others: norepinephrine, dopamine
and serotonin.  Whether or not nicotine influences CRF in the amygdala has not been
extensively documented except for recent study by (Matta, et al., 1997).  It is yet to be
documented whether or not nicotine also modulates CRF levels to achieve its CNS effects.
The effects of nicotine on CRF would certainly depend on dose and the duration of the
treatment and nicotine withdrawal would possibly have a different outcome.  From the
discussed literature, it can be assumed that if nicotine is anxiogenic, acute doses would
transiently increase CRF in rat amygdala and hypothalamus or decrease the content if it is
anxiolytic, while causing a decrease in the brain stem.  Chronic nicotine on the other hand
would cause increased content of CRF in the hypothalamus and extrahypothalamic





The sample consisted of 104 male Sprague Dawley  rats (Hill Top, Hill Top, PA)
aged 2-4 months and weighing 250-450 grams.  Rats were kept at animal quarters of 
WVU Health Sciences Center, with 12 hour dark/light hours, food and water freely
available.  Controls  included untreated rats and saline (vehicle) treated to control for the
stress of injection. 
Drug Solutions
Nicotine hemisulfate salt (C10 H 14 N 2.½H 2, Molecular weight  = 213.3 grams,
Fisher Scientific) approximately 40% weight/volume (w/v) was kindly provided by Drs.
W.W. Fleming, and D.A. Taylor, (Pharmacology & Toxicology, WVU Health Sciences
Center).  Nicotine was prepared in 0.9% saline to 4.7 mM and 2.0 mM solutions and
stored in the refrigerator.  These nicotine solutions were equivalent to 1.0 mg/ml and 0.4
mg/ml respectively and were injected at 1.0 ml/kg body weight to give doses of 1.0 mg/kg
and 0.4 mg/kg.
It has been reported that 2-3 packs/day of 20 cigarettes per pack give a smoker
plasma levels of 40-80 ng/ml nicotine and in rat these are equivalent to 3-6 mg/kg/day
(Balfour and Fagerström, 1996; Isaac and Rand, 1972).  This makes a 20 cigarettes pack
equivalent to 1.5 mg/kg in rat.  In this study, the 1.0 mg/kg dose was chosen because it has
been commonly used by other researchers (Andersson, et al., 1981; Sastry, et al., 1995;
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Sharp, et al., 1993; Ulrich, et al., 1997).  For example, Sastry, et al., (1995) measured
nicotine in the brain after 1.0 mg/kg and reported that nicotine can be detected in the brain
from 5-50 after intravenous injection.  The 0.4 mg/kg dose has also been frequently used
by other researchers (Benwell and Balfour, 1985; Johnson, et al., 1995; Sharp, et al.,
1993), and is half of the 0.8 mg/kg dose which is equivalent to plasma concentrations of
nicotine elicited by smoking one 10 pack of cigarettes, that is, 10-25 ng/ml (Benowitz, et
al., 1988; Isaac and Rand, 1972).
Animal treatment procedure
Rats were treated and sacrificed between the hours of  9.00 am to 12.00 noon to
capitalize on the time before changes influenced by diurnal rhythms (Leal and Moreira,
1996; Owens, et al., 1990).  Two doses of nicotine were used for acute treatments; 0.4
mg/kg intraperitoneal (ip) nicotine at 15 and 30 minute treatment, and 1.0 mg/kg (ip) at 15,
30 and 60 minute treatments.  Each time treatment was an individual experiment with 12-
24 rats.  As indicated on Tables 1 and 2, six animals received 0.4 mg/kg nicotine for 15 or
30 minutes and six to eight animals received 1.0 mg/kg nicotine for 15, 30, or 60 minutes,
respetively. 
Animals were weighed and a nicotine or saline solution of  0 .25-0.45 ml was
injected to  rats according to their weights.  A 5-10 minute interval was allowed to
interspace the injections and facilitate the treatment procedure.  Rats were kept at 3-4 per
cage during the procedure.  The behavior of nicotine treated rats was observed during the
duration of the treatment.  After the duration of a given time point, animals were 
59
Table 1
Sample and dosing for micro-punch dissections
---------------------------------------------------------------------------------------------------------
Experiment n Time (minutes) *Nicotine dose
(mg/kg)
---------------------------------------------------------------------------------------------------------
1 12 15  0.4




*Four to six  animals received nicotine per time point
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Table 2
Sample and dosing for macro-dissections
---------------------------------------------------------------------------------------------------------
Experiment n Time (minutes) *Nicotine dose
(mg/kg)
---------------------------------------------------------------------------------------------------------
3 24 15 1.0
4 24 30 1.0




*Eight animals received nicotine per time point
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decapitated and brains carefully removed from cranium, placed in vial with temporal lobe
facing away from the surface, vial capped and immediately frozen in liquid nitrogen.  The
brains were kept in dry ice box and later stored at -70C before dissections.    For each rat,
trunk blood was collected into labeled microcentrifuge tubes (immediately after
decapitation) for corticosterone  assays.  These were kept in ice and later centrifuged at
3000 rpm for 30 minutes using a cold microcentrifuge.  Plasma was separated (using a
Pasteur pipette) into a new set of labeled microcentrifuge tubes and then stored at  -20C
until corticosterone radioimmunoassay. 
Cryostat frozen sections of the brain
 The cryostat-micro-punch procedure was the initial method in this study and was
used only on animals treated with 0.4 mg/kg (ip) nicotine at 15 and 30 minutes.  The
cryostat, (Micron, GmbH, HM 505E, Germany, Walldorf.) was provided by Dr. W.T.
Stauber, Physiology Department, WVU and Dr. J. Flores, Biology Department, WVU.  A
12 centimeter blade (Leica Instruments) was used for sectioning, with cryostat temperature
maintained at -6C to-10C.   For each brain, coronal sections of 300 microns were made
(Palma and Brownstein, 1985).  The sections were placed onto 10-15 labeled glass slides
and kept frozen in slide box placed in closed dry ice container and later stored at -20C,
until the micro-punch procedure.  
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Micro-punch dissections of brain nuclei
The micro-punch dissection method of (Palma and Brownstein, 1985), was used to
obtain nuclei from cryostat coronal sections.  The amygdaloid nuclei, paraventricular
nucleus of the hypothalamus and locus coeruleus/parabrachial nucleus (LCPB) were
obtained separately to give three samples for each animal.  Micro-punches were
accomplished by using a 1 mm or 2 mm curette with slide placed on a glass petri dish
placed on dry ice.  The rat brain atlas (Paxinos and Watson, 1986) was used to decipher
the  landmarks; the amygdala distributed on plates 25-32, PVN plates 20-25 and LCPB
plates 52-59.  Tissue were immediately placed in labeled tubes containing 2.0 ml ice-cold
0.5N HCl solution containing 1.0 mg/ml ascorbic acid and 1.0% Triton X-100, for
extraction.  Homogenization of samples was accomplished with ultrasonic disruption
(sonication) at setting 3 (Branson Sonic Power, Branson instruments Inc. Melville, L.I.
NY).   Samples were heated at 70C for 10 minutes to denature enzymes and then stored
at -70C until lyophilizations and protein assays.  In this procedure, it is assumed that CRF
is spared from denaturation because it is a low molecular weight peptide.  The cryostat-
micro-punch method had both advantages and disadvantages.
Advantages 
1. Good sections are obtained and different nuclei in a region could be accessed with
different size curettes.
2. All the three regions per animal could be punched out in one sitting, the sequential
order of sections allowed for an ordered access to the specific nuclei.  
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3. Curettes allowed for a more accurate access to nuclei and less extraneous tissue
was obtained.
Disadvantages
1. The method is labor intensive, have to give identification numbers and use about
10 or more glass slides to obtain three to four coronal sections per slide.  Only four
to five brains could be punched out per day because of setting up and micro-
punching out the three regions which were distributed in four or more slides.
2. If the brain separated from the chuck amidst sectioning, some sections were likely
lost in the process of readjusting to the appropriate width.  
3. If the integrity of sections was compromised, nuclei were not easily accessed,
therefore loss of CRF could have occurred and thus contribute to the variability in
the results. 
4. Caution needed to be taken as to avoid the formation of mist from the dry ice as
this turned cloudy and camouflaged the tissue when the mist settled on the glass
slide.
5. With this method, it took about five weeks or more to obtain the final results
depending on the number of animals used.        
Macro-dissections of brain regions
This procedure of macro-dissection was used on brains of animals treated with 1.0
mg/kg (ip) nicotine at 15, 30 and 60 minutes.  This followed the dissection method for
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slice experiments, already established in the laboratory.  For the amygdala, the temporal
lobe was targeted, the whole of the hypothalamus and median eminence are obtained
together and the whole of the brain stem was accessed.  Dissections were accomplished by
placing brain on glass petri dish mounted on ice and using a scalpel.  Tissue were
immediately placed in labeled tubes containing 3.0 ml ice  cold 0.5N HCl solution
containing 1.0 mg/ml ascorbic acid and 1.0% Triton X-100, for extraction.  
Homogenization of samples was accomplished with ultrasonic disruption (sonication) at
setting 3 (Branson Sonic Power, Branson instruments Inc. Melville, L.I. NY).  Samples
were heated at 70C for 10 minutes to denature enzymes and then stored at -70C until
lyophilizations and protein assays (Clarke and Gillies, 1988; Smith, et al., 1986).   The
method has advantages and disadvantages.
Advantages 
1. The method was fast, 12 brains (three regions each) could be dissected, and
homogenized in one day. 
2. The sequential removal of unwanted tissue resulted in easy access to the regions of
interest. 
3. There was little likelihood of living any nuclei out.  
Disadvantages 
1. The method allowed for extraneous tissue to be obtained which made samples need
to be more dilute (3.0 ml instead of 2.0 ml used with nuclei).  
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2. For the amygdala, the whole of the temporal lobe was accessed, and CRF levels
would reflect levels from neighboring areas including piriform cortex .
3. The median eminence was obtained and this would augment hypothalamic CRF to
about 10 times the levels in PVN (Chappell, et al., 1986). 
4. Assaying the whole brain stem did not only involve the PBN and LC but also the
other nuclei including, nucleus tractus solitarius, raphe nuclei, dorsal vagal
complex and Barrington’s nucleus, nuclei which also contain CRF. 
5. With brain stem, the increased amount of tissue in some samples reduced the
available supernatant after micro-centrifugation.  Extreme care was needed to
minimize agitation of supernatant.
6. Overall, results from the two methods; micro- and macro-dissections could not be
compared, because two variables were different, the dose and dissection method. 
Lyophilization of acidic extracts
Each animal had three brain regions to be assayed for both radioimmunoassays
(RIA) and Lowry protein assays.  The two different dissection methods produced two sets
of samples brain region and nuclei (Table 3).  For each animal and per brain region, a 500
l HCl extract was microcentrifuged using the Eppendorf table-top microcentrifuge at
14,000 rpm for 30 minutes.  Parallel to samples, 500 l of 0.5N HCl was also
microcentrifuged to be used in RIA buffer matrix.  A 300 l aliquot of supernatant was
transferred to another labeled microcentrifuge tube.  The 300 l samples and HCL were
lyophilized (freeze-dried in vacuum) using Savant Speed Vac concentrator, for three to 
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Table 3
Assayed brain regions and nuclei
---------------------------------------------------------------------------------------------------------
Micro-punch dissections Macro-dissections




Locus coeruleus/parabrachial nucleus Brain stem
---------------------------------------------------------------------------------------------------------
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four hours with heat or overnight without heat.  The lyophilate was stored at - 70C until
radioimmunoassay for CRF.  For the assay, acidic lyophilized extracts were resuspended
in 1.5 ml RIA buffer (30 mM phosphate buffer with 25 mM EDTA, containing 0.1 ml
Triton X-100 and 0.02 mg/ml aprotinin).  A 300 l aliquot of this solution was used for
the radioimmunoassay of CRF. 
Radioimmunoassays
 Radioimmunoassay (RIA) is the measurement of concentration of antigen (e.g.
hormone) by determining the extent to which it combines with antibody.  A limited
amount of antibody is reacted with the corresponding hormone (CRF, corticosterone)
labeled with a radioisotope.  Upon addition of an increasing amount of hormone, a
corresponding decrease in amount of labeled hormone is bound to the antibody.  The
secondary antibody recognizes and binds the antibody bound CRF or corticosterone.  After
separation of bound and unbound labeled hormone, the amount of radioactivity in the
bound fraction is calculated and used to construct a standard curve against which
concentrations of unknown samples are measured.  Non specific binding (NSB) is
determined in the absence of antibody.
Corticotropin releasing factor (CRF) radioimmunoassays
The method of Vale, et al., (1983), was used for the RIA for CRF.  RIA on
lyophilized 300 l of  CRF extracts (per brain region) were done with a C-terminal
directed rabbit anti-human/rat CRF antibody, RC 70, (provided by Dr. Wylie Vale, Salk
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Institute, San Diego, CA) and 125I-iodohistidyl-CRF (Amersham, Arlington Heights, IL). 
After treatment with secondary antibody, (anti-rabbit gamma globulin), the antibody-CRF
complex was precipitated using 2% polyethylene glycol (Sigma, St Louis, MO).  Amount
of radioactivity in the complex (pellet) was counted for two minutes on the gamma counter
(Wallac-1470 Wizard automatic gamma counter, Wallac Inc, Gaithersburg MD).
Procedure
Day 1:  RIA buffer  (30 mM phosphate buffer with 25 mM EDTA, containing 0.1
ml Triton X-100 and 0.02 mg/ml aprotinin).  A lyophilized CRF standard of 200,000
pg/tube stored at -70C freezer was reconstituted fresh on day of use, with 1 ml of RIA
buffer to make tube #A1.  Primary antibody was rabbit anti-rat CRF, 50 l aliquots were
stored in Fisherbrand microcentrifuge tubes  at -70C.  The 50 l aliquot of antibody
(1:250) was combined with 450 l  RIA buffer.  Rabbit serum was stored in -20C freezer
in 300 l aliquots and primary antibody (Ab) cocktail consisted of RIA buffer, rabbit
serum and the antibody, at a final concentration of 1:500,000.  Buffer matrix was made of
lyophilized HCL resuspended in 1.5 ml RIA buffer and pooled together.
 Standards were prepared in labeled Sarstedt polypropylene (75 x 12 mm) tubes by
serial dilution of tube #A1 with RIA buffer and concentrations of standard ranged from 
0-25 pg/l.  A volume of 20 l of the standard was injected into appropriate tubes.  The
zero CRF standard was done in quintuplicate and the rest were done in triplicates.  An
aliquot of 300 l of buffer matrix was mixed with an appropriate standard (20 l) in a
standard polypropylene tubes.  Two nonspecific binding tubes were prepared, in which the
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standards and primary antibody were replaced by an equivalent amount of RIA buffer.  
The lyophilized acidic samples and HCL extracts were thawed, reconstituted with 
1.5 ml RIA buffer, vortexed and then microcentrifuged for approximately two minutes.  A
300 l aliquot of diluted lyophilate was injected into three labeled tubes (for triplicates)
and 20 l sample matrix was added to maintain a volume equal to standards.  A volume of
100 l of primary antibody cocktail final concentration, 1:500,000 was added to standards
and samples (except nonspecific binding tubes).  The tubes were shaken gently to mix,
covered with parafilm and then incubated at 4C for at least 24 hours.
Day 2.  The lyophilized label (125Iodohistidyl-CRF, Amersham) was diluted (on day of
arrival) with 200 l RIA buffer containing 0.1% acetic acid and stored at -70C in 10 l
aliquots (0.5 Ci).   125I-CRF (10 l) was reconstituted with RIA buffer in plastic beaker
for 100 l/tube (on day of use).  The activity of  125I-CRF solution was measured on the
gamma counter before addition to assay.   When fresh, a 10l aliquot diluted to 12 ml RIA
buffer yielded approximately 10,000-12,000 cpm/100 l (counts per minute).  
Adjustments were made to buffer volumes according to age of  label.  100 l  of 125I-CRF
solution (>10,000 cpm/tube) was added to all the tubes, after which the tubes were shaken
gently, covered with parafilm and further incubated for at least 20-24 hours at 4C
(refrigerator). 
Day 3.   Precipitating solution was composed of polyethylene glycol (PEG, ( 1.45
g/10 ml buffer) secondary antibody and made fresh on day of use.   Secondary antibody
(sheep anti-rabbit IgG) stored in 2.0 ml aliquots in -20C freezer was diluted 1:4 with RIA
buffer.   A volume of 100 l of secondary antibody was added to each tube, after which
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100 l of PEG solution (final concentration 2%) was added and the contents vortexed. 
The tubes were covered and incubated for 20 minutes at room temperature for
precipitation, and then centrifuged at 4000 g for 20 min (5,000 rpm, on Sorvall centrifuge). 
The  supernatant which contained unbound radioactive CRF was aspirated and
radioactivity of pellets counted for two minutes on the gamma counter (Wallac-1470
Wizard automatic gamma counter, Wallac Inc, Gaithersburg MD)
Corticosterone radioimmunoassays 
The ImmuChemTM double antibody 125I corticosterone RIA kit for rat and mice was
used to assay plasma samples for all tested rats.  The kit was stored in a 4C refrigerator
until day of use.  The contents of the kit were as follows:
a. Steroid diluent, a phosphate gelatin buffer (ph 7.0 ± 0.1) containing rabbit gamma
globulin.
b Anticorticosterone (corticosterone-3-carboxymethyloxamine) developed using bovine
serum albumin (BSA) as the antigen. 
c. Six corticosterone calibrators (standards) with concentrations ranging from 25-1000
ng/ml. 
d. Precipitating solution was a mixture of polyethylene glycol (PEG) and goat anti rabbit
gamma globulins contained in TRIS buffer.
e. The corticosterone 125I derivative, a 0.2 ml aliquot of this radioactive derivative would
provide approximately 50,000 cpm at 75% counter efficiency, on day of shipment.
f.  Prediluted lyophilized form of rat corticosterone controls (0.1 ml each).  The high
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control had corticosterone levels of 517-777 ng/ml and the low control had 78-112
ng/ml.     
Procedure
All contents of the kit were brought to room temperature before use.   Rat plasma
sample was diluted 1:200, by adding 10 l plasma to 2.0 ml steroid diluent, the contents
were mixed using a vortex mixer and 100 l was assayed.  For assay, glass test tubes of
size 12 x 75 mm were used and samples were assayed in triplicates.  The procedure was
followed as directed  in the kit.  The tubes were mixed thoroughly and centrifuged in
Sorval centrifuge, at 2300 to 2500 rpm (1000 g) for 15 minutes.  The supernatant
containing unbound radioactivity, was aspirated and the precipitate was counted in the
Gamma counter (Wallac-1470 Wizard automatic gamma counter, Wallac Inc,
Gaithersburg MD) for two minutes.
Protein determination on acidic extracts 
 The Lowry protein assay method was employed to measure protein levels in all six
sets of acidic samples (Table 3); for use in the determination of CRF content relative to the
protein obtained from macro-dissections and micro-punches.  The Lowry protein assay is
based on interaction of proteins with the phenol reagent and copper under alkaline
conditions.  The blue color reaction arises from  a copper catalyzed oxidation of aromatic
amino acids and other groups by the heteropolyphosphate reagent (Lowry, et al., 1951;
Pomeranz and Meloan, 1987).  The intensity of the blue color is not strictly proportional to
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the amount of protein in the sample, and the assay has a narrow linear range of between 10
to 70 g protein.  The method was appropriate for this study though, because samples
were of similar type, from same brain regions and were highly dilute.  Assuming that most
tissue is about 95% water and 5% protein,  levels would be approximately 5g protein per
milligram tissue weight.  The brain would contain lower levels of  protein because of its
high lipid content.
Procedure
An aliquot of the HCl homogenate of brain region samples was placed in 12 x 75
glass tube and then combined with 1N NaOH to make a total volume of 500 l.  The tubes
were sealed and  refrigerated until the protein assay.  On day of assay, Bovine serum
albumin (BSA) standard (1.0 mg/ml) was prepared using distilled water.  Standard
solutions of 0, 5, 10, 20, 30, 50, 60, 80 and 100 l (0-100g) were aliquoted into 13 x 100
mm glass tubes.  The volume was made up to 100 l using 1N (NaOH).  Standards and
samples were run in triplicates.  For assay, a 50 l or 100 l aliquot of alkaline sample
was pipetted into 13 x 100 mm glass tube and the volume made up to 100 l with 1N
NaOH.
The Lowry reagents were 2% sodium carbonate (Na2CO3), 1 % copper sulfate
(CuSO4), 2% sodium tartrate and 2N Folin phenol reagent.  The blue color was read on




Treatment of data 
Radioimmunoassay results (gamma counts) for both CRF and corticosterone were
coded into a Microsoft Excel spreadsheet.  Since all standards and samples were run in
triplicates, counts from the blank were subtracted from all standard or sample counts and
an average of  triplicates was obtained.  A standard curve was constructed and regression
analysis used to calculate  concentrations.  Percent binding was related to counts per
sample, divided by total counts added and at low amounts of CRF, there was high binding
of radioligand, that is, more counts, and vice versa.  The ratio of binding per sample to the
zero level (B/B0) was obtained and a plot against the log of standard CRF concentrations
gives sigmoidal curve.  The curve was converted to a straight line by plotting logit (natural
log)  B/B0/1-B/B0 against the log of standard CRF concentrations, after which the
concentration of the standard and samples were obtained.  To obtain CRF content in brain
regions, all dilutions employed, from dissections to radioimmunoassays, were accounted
for.  Taking into consideration that 2.0 ml or 3.0 ml HCL was the original dilution, with a
300 l aliquot lyophilized, resuspended in 1.5 ml RIA buffer and 300 l assayed, the final
dilution factor was 35 or 50 respectively. 
Protein assays were run on all the brain regions for both doses and treatment time
points.    Absorbance values were coded into a Microsoft Excel spreadsheet.  Results from
the blank were subtracted from all standard or sample counts and an average of triplicates
was obtained.  A standard curve was constructed and regression analysis used to calculate
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concentrations.  To obtain the original amount of protein in each sample, the protein in the
assayed 50 l or 100 l was converted to the 1:500 aliquot and finally to content in 3.0 ml
or 2.0 ml of the acidic sample.  For each brain region and treatment, protein levels were
grouped together and average protein obtained per brain region/nucleus was calculated, for
all time points, to indicate the average amount of protein obtained with dissections. 
However, individual protein values per sample were used to calculate concentration in
picograms of CRF per milligram of protein (pg CRF/mg protein) for the corresponding
sample.  For example, rat number one after treatment for fifteen minutes with 0.4 mg/kg
nicotine had three samples; amygdaloid nuclei, paraventricular nucleus and brain stem
nuclei.  The protein value from the each brain-region-sample was used to calculated CRF
content, that is, amygdaloid samples (CRF and protein) for rat #1 in the 0.4 mg/kg group
were used correspondingly.
An overall mean protein concentration (pg CRF/mg) of the untreated groups per brain
region was used for comparisons with means of nicotine and saline treated rats.  A factor
was calculated to normalize individual experiments to an overall mean of the untreated
group.  This was achieved by grouping together pg CRF/mg protein for untreated rats, per
brain region, at all treatment time points, after which gross mean was calculated.  For
example, CRF levels for amygdaloid nuclei of untreated rats at 15 and 30 minutes time
points were grouped and their gross mean calculated.   After calculating mean CRF levels
of untreated rats per treatment time point, the gross mean was divided by the mean for
untreated rats for each time point to get the factor for normalizing individual experiments. 
This factor was used to multiply individual values of pg CRF/mg protein.  
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Final concentration values were grouped according to treatments and then used for
statistical comparisons.  The outlier test was used for individual experiments to discard
any value  x -2SD or  x +2SD.  
Statistics  
Data was analyzed using the Microsoft Excel spreadsheet and GB-Stat statistical package. 
Descriptive statistics (mean, SD and SE), two way (time, treatment) analysis of variance
(ANOVA) and post-hoc comparison by Tukey’s t-tests were used to test for statistical
significance.  Hypotheses were tested using the critical probability values of alpha at  p 





Errors could have arisen from a number of stages in the procedure of this study
including: storage, sectioning, dissections, pipetting and individuality of animals.  On the
cryostat, technical errors led to minor losses due to deformities in some sections and
micro-punch dissections depended mainly on the integrity of the sections.  Macro-
dissections were possibly not completely uniform and this could have led to an unevenness
in amount of tissue obtained thus causing a variation in amount of CRF relative to protein. 
Pipetting errors in all various stages of the  experiment including lyophilization and
radioimmunoassays could introduce variability in results.   Over-aspiration of radioactive
supernatant could have led to minute losses of pellet with loss of radioactive counts, and
under-aspiration could leave droplets of radioactive material, leading to an over-estimation
of counts.  Another source of error could arise from the protein assay where pipetting
could introduce errors that could over- or under-estimate protein levels.  In corticosterone
assays, errors could have arisen mainly from pipetting and aspiration of the radioactive
material.  Control rats, being not under the influence of the stress of injection could have
had enhanced variability due to the individuality of the animals.
Animal observations
Nicotine treated rats exhibited tremors, fast breathing and mild convulsions a minute
after the injection.  They also showed paralysis of the hind limbs and decreased
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locomotion which agrees with previous observations that high doses of nicotine decrease
locomotion in drug naive rats (Armitage, et al., 1969; Hakan and Ksir, 1991).  On the
separation of plasma, it was noted that some blood samples had lysed.  Lysis does not
affect the corticosterone levels, and use of either plasma or serum exhibits no variation in
corticosterone levels.  Generally, for micro-punch dissections (brain nuclei) CRF levels for
untreated groups were comparable at all time points.  Similarly, saline treated rats showed
no significant differences at the two treatment time points.  The same pattern was observed
in macro-dissections for 15 and 30 minutes time points, but for the brain stem, the 60
minute time point had considerable high levels of CRF compared to 15 and 30 minutes
and this may have been due to inconsistences in decapitations and dissections. 
Expected results
Studies on nicotine pharmacokinetics indicated that nicotine accumulates in the rat
brain within five minutes after intravenous injection (Sastry, et al., 1995; Schmiterlöw, et
al., 1967).   Nicotine peaks at about 20 minutes, with levels remaining high for up to 50
minutes but declined by 60 minutes.  In this study, it was assumed that the response of
CRF after 15 minutes treatment would correspond to the peaking of nicotine in the brain
while the 60 minutes response would correspond to the relatively low levels.  For the
present study, if nicotine is anxiogenic, we should expect that acute doses of  0.4 mg/kg or
1.0 mg/kg would elavate CRF content in the amygdala and hypothalamus, while
decreasing CRF, if nicotine is anxiolytic or antidepressive.  Corticosterone levels were
utilized as positive control for nicotine effects.  Results are presented such that
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corticosterone is addressed first.  Even though microdissections were the initial method
used, whole regions: hypothalamus, amygdala and brain stem are addressed before their
nuclei.
Plasma corticosterone
Figure 1 shows plasma corticosterone levels after 15 and 30 minutes treatment with
0.4 mg/kg nicotine.   Results are expressed in nanograms/milliliter (ng/ml), mean ± S.E.M
per treatment.  After 15 minutes treatment, mean corticosterone levels were 368 ± 32, 291
± 79 and 178 ± 71 for nicotine, saline and untreated respectively.  The thirty minute time
point exhibited values of 473± 39, 174 ± 39 and 199  ± 53 for nicotine, saline and
untreated rats respectively.  Fifteen minutes treatment with nicotine produced significant
effects compared to no treatment and 30 minutes nicotine produced significant effects
compared to both saline treated and untreated rats. 
Shown on Figure 2 are serum corticosterone levels 15, 30 and 60 min after treatment
of rats  with 1.0 mg/kg nicotine.  Results are expressed in ng/ml, mean ± S.E.M per
treatment.  After 15 minutes treatment, mean corticosterone levels were 364 ± 45, 220 ±
36 and 111 ± 24 for nicotine, saline and untreated respectively.  The 30 minute time point
exhibited values of 216 ± 28, 134 ± 26 and 111 ± 24 for nicotine, saline and untreated rats
respectively.  After 60 minutes  treatment, mean corticosterone values of 306 ± 65, 
83 ± 31 and 111 ± 24 for nicotine, saline and untreated rats respectively were observed.  
Significant effects of nicotine were observed at 15, 30 and 60 minutes versus untreated





























Figure 1.   Plasma corticosterone levels after 15 and 30 minutes treatment with nicotine
0.4 mg/kg, 0.9% saline (vehicle 1.0 ml/kg) or no treatment: 15 minutes nicotine (n = 4),
saline (n = 4) and untreated (n =4), 30 minutes nicotine (n = 8), saline (n =8) and untreated
(n = 8).  Values are expressed in ng/ml, mean ± S.E.M per treatment.  *denotes significant
effect of nicotine versus sham and ‡ denotes significant effects of nicotine versus saline, P
































Figure 2.   Plasma corticosterone levels after 15, 30 and 60 minutes treatment with
nicotine 1.0 mg/kg, 0.9% saline (vehicle, 1.0 ml/kg) or no treatment: 15 minutes nicotine
(n = 6), saline (n = 8) and untreated (n = 6), 30 minutes nicotine (n = 6), saline ( n = 6) and
untreated (n = 7), and 60 minutes nicotine (n = 4), saline (n = 4) and untreated (n = 7). 
Values are expressed in ng/ml, mean ± S.E.M per treatment.  *denotes significant effect of
nicotine versus sham and ‡ significant effects of nicotine versus saline, P  0.05, ANOVA
and Tukey’s t test.  Overall treatment effect at 1.0 mg/kg nicotine F = 8.6 (2,53) p =
0.0007.  Overall time effect at 1.0 mg/kg nicotine F = 3.27 (2,53) p = 0.05. 
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Summary of protein levels for all experimental rats
Lowry protein assay results for each dissection and all time points were summarized
to indicate the average of amount of protein obtained in dissections.  Individual protein
values were used to convert corresponding values of CRF to picograms CRF per milligram
protein.  Values are expressed in milligrams (mg), mean ± S.E.M.   A summary of protein
levels from micro-punch dissections on animals treated with 0.4 mg/kg nicotine for 15 and
30 minutes indicated that in amygdaloid nuclei, mean levels of 3.16 ± 0.16 mg protein
were obtained.  The paraventricular nucleus and locus coeruleus/parabrachial nucleus had
mean protein levels of 1.53 ± 0.08 mg and 1.89 ± 0.14 mg respectively.  For macro-
dissections on animals treated with 1.0 mg/kg nicotine for 15, 30 and 60 minutes, brain
stem samples contained more protein (mean = 61.12 ± 2.08 mg) compared to
hypothalamus and amygdala with means levels of 21.10 ± 0.59 mg and 36.27 ± 0.92 mg
respectively.   
CRF content in the rat brain after nicotine treatment
CRF content in untreated rats
Figure 3 is a summary of CRF content in brain regions of untreated rats for both
micro- and macro-dissections at all tested time points.  Values are expressed in pg
CRF/mg protein (mean ± S.E.M).  CRF levels were higher in micro-punch dissections
compared to macro-dissections and this was to be expected, because micro-punches were
more precise at targeting areas where CRF is more concentrated.  Comparison of mean pg
CRF/mg protein in micro-punches of all the three brain nuclei revealed that in micro-
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Figure 3.  CRF content (pg CRF/mg protein) in untreated rats.  Comparison of mean CRF
content in: (1) micro-punches (0.4 mg/kg treatments) of all the three brain nuclei,
paraventricular nucleus (PVN), amygdaloid nuclei and locus coeruleus/parabrachial
nucleus (LCPB) and (2) macro-dissections (1.0 mg/kg treatments) of three brain regions,
hypothalamus, amygdala and brain stem of untreated rats.  Values are expressed in pg
CRF/mg protein, mean ± S.E.M per treatment. ¶ Denotes significant differences between
hypothalamus versus amygdala and † denotes significant differences between
hypothalamus versus brain stem.  
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punches, the locus coeruleus/parabrachial nucleus region had generally higher levels of
CRF compared to PVN and amygdaloid nuclei, although this was not statistically
significant.  These results are agreeable with those reported by Chappell, et al., (1986), in
that study, controls had CRF levels of approximately 500 pg/mg, 600 pg/mg and 800
pg/mg for PVN, amygdala and brain stem respectively.  In macro-dissections, the
hypothalamus had significantly increased levels compared to amygdala and brain stem. 
This is consistent with the fact that the median eminence contains the highest levels of the
neuropeptide (Chappell, et al., 1986; Palkovits, et al., 1985).    
CRF content in hypothalamus and paraventricular nucleus (PVN)
It was hypothesized that there would be significant increases in hypothalamic CRF
levels in nicotine treated rats compared to untreated and saline treated rats, at a given dose
and time point.  Figure 4 shows CRF content in macro-dissections of rat hypothalamus
after 15, 30, and 60 treatment with 1.0 mg/kg nicotine.  Values are expressed in pg
CRF/mg protein, mean ± S.E.M per treatment.  Mean CRF content for untreated rats from
the three time points was 240 ±16 and this was compared to means of nicotine and saline
treatments.  At the 15 minute time point, mean  CRF levels were 338 ± 50 and 290 ± 20
for nicotine and saline rats respectively.  After 30 minutes, mean CRF levels were 231 ±
30 and 236 ± 21 for nicotine and saline rats respectively.  Sixty minutes of treatment
exhibited mean CRF levels of 252 ± 24 and 289 ± 32 for nicotine and saline respectively. 
CRF levels were significantly higher in rats treated with nicotine for 15 minutes compared
to untreated.
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Figure 4.   CRF content in macro-dissections of hypothalamus after 15, 30 and 60 minutes
treatment with nicotine 1.0 mg/kg, 0.9% saline (vehicle, 1.0 ml/kg) or no treatment: 15
minutes nicotine (n = 8), saline (n = 8), 30 minutes nicotine (n = 8), saline ( n = 8), 60
minutes nicotine  (n = 7), saline ( n = 7) and total untreated (n = 17).  Values are expressed
in pg CRF/mg protein, mean ± S.E.M per treatment.  *Denotes significant effects of
nicotine versus untreated rats at 15 minutes treatment, and ‡ significant time effects for
nicotine 15 versus 30 minutes,  P  0.05 ANOVA and Tukey’s t-test.  The overall
treatment effects at 1.0 mg/kg nicotine were F = (2, 96) p = 0.039. 
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No significant effects were observed between saline and nicotine treated rats.  Significant
time effects were seen between 15 minutes and 30 minutes nicotine treated groups. 
 A summary of CRF content in micro-punches of PVN after 15 and 30 min treatment
with 0.4 mg/kg nicotine is shown on Figure 5.  Values are expressed in pg CRF/mg
protein, mean ± S.E.M per treatment.  Mean CRF content for untreated rats from both time
points was 445 ± 70 and this was compared to means of nicotine and saline treatments. 
After 15 minutes treatment, mean CRF levels were  447 ± 51 and  495 ±26 for nicotine
and saline respectively.  The thirty minute time point exhibited values of 531 ± 72 for
nicotine and 568 ± 69 for saline treated rats.  No significant effects were observed between
nicotine versus saline versus untreated group and there were no significant time effects. 
CRF content in amygdala and amygdaloid nuclei
The hypothesis was that there would be significant increases in amygdaloid CRF
levels in nicotine treated rats compared to untreated and saline treated rats, at a given dose
and time point.  Figure 6 summarizes the CRF content in macro-dissections of rat
amygdala after 15, 30, and 60 treatment with 1.0 mg/kg nicotine. Values are expressed in
pg CRF/mg protein, mean ± S.E.M per treatment.  As the figure shows, mean CRF content
for untreated rats from the three time points was 106 ± 10.  At the 15 minute time point,
mean  CRF levels were 128 ± 15 and 115 ± 9 for nicotine and saline rats respectively. 



























Figure 5.    CRF content in micro-punches of paraventricular nucleus of the hypothalamus
after 15 and 30 minutes treatment with nicotine 0.4 mg/kg, 0.9% saline (vehicle 1.0 ml/kg)
or untreated: 15 minutes nicotine (n = 4), saline (n = 4), 30 minutes nicotine (n = 8), saline
(n = 7) and total untreated group (n = 8).  Values are expressed in pg CRF/mg protein,
mean ± S.E.M per treatment.
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Figure 6.    CRF content in macro-dissections of amygdala after 15, 30 and 60 minutes
treatment with nicotine 1.0 mg/kg, 0.9% saline (vehicle, 1.0 ml/kg) or no treatment: 15
minutes nicotine (n = 8), saline (n = 8), 30 minutes nicotine (n = 8), saline ( n =7), 60
minutes nicotine (n = 7), saline ( n = 7) and total untreated (n = 23).  Values are expressed
in pg CRF/mg protein, mean ± S.E.M per treatment.
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Sixty minutes of treatment exhibited  mean CRF levels of 106 ±10 and 99 ± 13 for
nicotine and  saline respectively.  No significant treatment and time effects were observed
between nicotine versus saline versus untreated group at all time points.
Shown on Figure 7 is CRF content in micro-punches of amygdaloid nuclei after 15
and 30 min treatment with 0.4 mg/kg nicotine.  Values are expressed in pg CRF/mg
protein, mean ± S.E.M per treatment.   Untreated groups from both time points had a mean
of 390 ± 32.  After 15 minutes treatment mean CRF levels were  471 ± 80 and 417 ± 68
for nicotine and saline respectively.  The thirty minute time point exhibited values of 331
± 25 for nicotine and 362 ± 29 for saline treated rats.  No significant treatment effects were
observed between nicotine versus saline versus untreated group, at all time points. 
However, the Tukey’s t-test indicated that significant time effects occurred in the nicotine
treated group in that, when compared to the 15 minutes group, the 30 minutes nicotine
treated rats had significantly decreased levels of CRF in the amygdala. 
CRF content in brain stem and the locus coeruleus/parabrachial nucleus 
It was hypothesized that there would be significant decreases in brain stem CRF
levels in nicotine treated rats compared to untreated and saline treated rats, at a given dose
and time point.  Figure 8 shows a summary of CRF content in macro-dissections of rat
brain stem after 15, 30, and 60 treatment with 1.0 mg/kg nicotine.  Values are expressed in
pg CRF/mg protein, mean ± S.E.M per treatment.  Mean CRF levels of untreated rats from
both time points were 101 ± 7.  After 15 minutes treatment, mean  CRF levels were 100 ±

























Figure 7.  CRF content in micro-punches of amygdaloid nuclei after 15 and 30 minutes
treatment with nicotine 0.4 mg/kg, 0.9% saline (vehicle 1.0 ml/kg) or no treatment: 15
minutes nicotine (n = 4), saline (n =48), 30 minutes nicotine (n = 8), saline (n = 7) and
total untreated group (n = 8).  Values are expressed in pg CRF/mg protein, mean ± S.E.M
per treatment.  *Denotes significant effects of treatment time for 15 minutes nicotine
versus 30 minutes, p  0.05 ANOVA and Tukey’s  t-test.  Overall treatment effects at 0.4
mg/kg F = 3.6 (1,36) p = 0.069.
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Figure 8.    CRF content in macro-dissections of brain stem after 15, 30 and 60 minutes
treatment with nicotine 1.0 mg/kg, 0.9% saline (vehicle, 1.0 ml/kg) or no treatment: 15
minutes nicotine (n = 8), saline (n = 8), 30 minutes nicotine (n = 7), saline ( n = 8), 60
minutes nicotine (n = 6), saline (n = 8) and total untreated (n = 24).  Values are expressed
in pg CRF/mg protein, mean ± S.E.M per treatment.  
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After 30 minutes, mean CRF  levels were 102 ± 5 and 106 ± 5 for nicotine and saline
treated rats respectively.  Sixty minutes of treatment exhibited  mean CRF levels of 111 ±
5 and 115 ± 7 for nicotine and saline respectively.   No significant treatment and time
effects were observed between nicotine versus saline versus untreated group, at all time
points.
Figure 9 summarizes CRF content in micro-punches of locus coeruleus and
parabrachial nucleus (LCPB)  after 15 and 30 minutes treatment with 0.4 mg/kg nicotine. 
Values are expressed in pg CRF/mg protein, mean ± S.E.M per treatment.  The figure
shows that mean CRF content in untreated rats from both time points was 570 ± 66.  After
15 minutes treatment, mean CRF levels were  433 ± 79 and 579 ± 79 for nicotine and
saline respectively.  The thirty minute  time point exhibited values of 512 ± 43 for nicotine
and 475 ± 14 for saline treated rats.  No significant treatment and time effects were
observed in brain stem nuclei.
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Figure 9.  CRF content in micro-punches of locus coeruleus and parabrachial nucleus
(LCPB) after 15 and 30 minutes treatment with nicotine 0.4 mg/kg, 0.9% saline (vehicle
1.0 ml/kg) or no treatment: 15 minutes nicotine (n = 4), saline (n = 4), 30 minutes nicotine
(n = 8), saline (n = 8) and total untreated group (n = 8).  Values are expressed in pg
CRF/mg protein, mean ± S.E.M per treatment.
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CHAPTER VI
DISCUSSION AND FUTURE DIRECTIONS
Discussion
Effects of nicotine on hypothalamic and extrahypothalamic CRF have not been
extensively reported.  A recent study by (Matta, et al., 1997), reported increased c-fos
expression in CRF positive neurons after low dose nicotine treatment.  The proto-
oncogene c-fos is an early indicator of neuronal activity, and this suggested that nicotine
induced neuronal activity in CRF expressing neurons.  The present study is the first to
assess effects of nicotine on the content of CRF in the whole hypothalamus, amygdala and
brain stem, and selected nuclei in these brain regions, at different time points.  The study
utilized two different doses of nicotine, 0.4 mg/kg and 1.0 mg/kg.  The 1.0 mg/kg dose
was examined for 15, 30 and 60 minutes whereas the 0.4 dose was examined for 15 and 30
minutes only.   
In this study, it was assumed that the response of CRF after 15 minutes treatment
would respond to the peaking of nicotine in the brain which occurs about 20 minutes after
intravenous administration while the 60 minute response would correspond to relatively
low levels of nicotine (Sastry, et al., 1995; Schmiterlöw, et al., 1967).  The assumption
was that acute nicotine would evoke changes in CRF content due to one or more of the
following: (I) increased release and utilization leading to decreased content, (II) increased
synthesis, processing or reuptake leading to increased levels, (III) decreased utilization and
degradation, leading to increased levels and (IV) inhibition of release leading to increase
levels.  The present study did not directly address these mechanisms but only 
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measured CRF content.  Electrophysiological, immunocytochemical, microdialysis and
molecular biological techniques would be necessary to further elucidate the mechanisms of
nicotine-induced changes in CRF content.  Corticosterone levels were utilized as positive
control for the presence of nicotine.  
Plasma Corticosterone after 0.4 mg/kg treatment
Rats treated with nicotine 0.4 mg/kg for 15 minutes had significantly increased levels
of corticosterone compared to untreated rats.  Thirty minutes treatment with nicotine
produced a strongly significant increase in levels of plasma corticosterone compared to
both saline treated and untreated.  These results confirm the results reported by other
researchers, that nicotine injection augments plasma corticosterone.  Corticosterone has
been reported to peak at 10 to 30 minutes after injection and persist for up to 60 minutes
(Benwell and Balfour, 1982; Cam and Bassett, 1983; Freund, et al., 1988). 
Plasma Corticosterone after 1.0 mg/kg treatment
Rats treated with nicotine 1.0 mg/kg at either 15, 30 or 60 minutes exhibited a
strongly significant increase in levels of plasma corticosterone compared to saline treated
and untreated.  There were no significant differences between 15, 30 and 60 minutes
treatment with nicotine.  These results also confirm the results by other researchers, that
nicotine injection increases plasma corticosterone peaking at 10 to 30 minutes, and these
increases persist for up to 60 minutes after nicotine injection (Benwell and Balfour, 1982;
Freund, et al., 1988; Cam and Bassett, 1983).  The present results also confirm that
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nicotine activates the release of hypothalamic CRF causing increases in plasma
corticosterone.  How long this release of  CRF continues is not clear; possibly the
persistently high corticosterone levels reflect the continued release of CRF until the usable
pool is depleted.  The strongly significant increases in corticosterone are agreeable with
the fact that nicotine administration augments plasma corticosterone which in turn quells
down CNS effects of nicotine (Caggiula, et al., 1993, Caggiula, et al., 1998).  This effect
may also be due to the contribution of peripheral effects of nicotine directly on the adrenal
cortex (Bugaski, et al., 1998; Malin, et al., 1997).  Although levels were lower in all
treatment groups at the 60 minutes time point compared to 15 and 30, nicotine treated rats
still showed corticosterone levels significantly higher than untreated.  The results further
suggest that the stress of handling animals is minimal as shown by the lack of
corticosterone response to saline injection.  
CRF content in brain regions
Two doses of nicotine 0.4 mg/kg and 1.0 mg/kg were used to study effects on CRF
content in hypothalamus, amygdala and brain stem.  As expected, the hypothalamus had
higher levels of CRF compared to amygdala and brain stem.  Overall, there were no clear
cut treatment effects of nicotine in all tested brain regions after 15, 30, and 60 minutes. 
The use of two different doses and methods may have confounded the results.  Employing




In macro-dissections of the hypothalamus there were significant treatment and time
effects.  Rats treated with 1.0 mg/kg nicotine showed a strongly significant increase in
levels of CRF in the hypothalamus after 15 minutes treatment.  Thirty minutes of
treatment did not produce differences between treatments but the time effects of nicotine
were prominent.  Compared to the 15 minutes treatment time point, CRF was significantly
decreased in the hypothalamus of nicotine treated rats after 30 minutes.  This decrease
persisted even though non-significantly, to 60 minutes. This decrease signified that CRF
had been released from the median eminence and transported to the pituitary to trigger the
release of ACTH thus causing the increased release of corticosterone from the adrenal
cortex.  The initial increase which was paralleled by increased corticosterone was probably
due to the nicotine-induced mobilization of pre-pro CRF from PVN resulting in increased
levels in whole hypothalamus, with this dose (1.0 mg/kg).  Increased utilization of CRF
could possibly lead to a decrease in PVN levels due to depletion of pre-pro CRF, with
time.  The micro-punch method to examinine individual nuclei would help determine
which nucleus of the hypothalamus has increased levels.  No effects of saline treated
versus untreated rats were observed signifying that the treatment and time effects were
specific to nicotine.
It would be expected that a significant rise in plasma corticosterone would be
paralleled by a significant fall in the hypothalamic CRF and our results showed this.  The
present results indicated that after an initial rise at 15 minutes, CRF in the hypothalamus
returned to baseline levels by 30 and 60 minutes after nicotine treatment.  This suggested
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an initial increase in processing of pre-pro CRF, which was followed by facilitation of
release and increased utilization.  The return to baseline levels was expectedly due to the
corticosterone feedback inhibition.  Notably, this initial increase in CRF after 15 minutes
was also paralleled by increased corticosterone levels, indicating that this time point may
be too early to detect feedback inhibition. 
Acute and chronic stress have been shown to reduce CRF-like immunoreactivity in
the ME while causing an increase in the anterior hypothalamus (Chappell, et al., 1986;
Feldman and Weidenfeld, 1996a).  Notably, Swanson and Simmons, (1989), and Makino,
et al., (1994), showed that administration of increasing doses of corticosterone to
adrenalectomized animals caused a decrease in CRF mRNA in the hypothalamus
confirming the feedback inhibition.  In animals and humans, increased anxiety or fear have
been reported to increase circulating levels of CRF and glucocorticoids (Nemeroff, et al.,
1991; Owens, et al., 1991) indicating a disregulation of the HPA axis.  Studying effects of
nicotine directly on corticosterone synthesis in adrenal cortex would be useful in
determining the direct contribution of nicotine to circulating corticosterone and to clarify
why increased levels of corticosterone were observable when CRF levels had returned to
baseline after 30 and 60 minutes.
Paraventicular nucleus
Acute and chronic stress have been shown to cause no changes in CRF-like
immunoreactiviy in the paraventricular nucleus (PVN)  (Chappell, et al., 1986; Feldman
and Weidenfeld, 1996a).  In the present study, microdissections of the PVN showed that
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there were no significant effects after 15 minutes treatment, for nicotine (0.4 mg/kg)
versus untreated versus saline injection.  A slight increase in CRF was observed in 30
minutes but was not statistically significant.  This would indicate that nicotine and the
saline injection induced the processing of  pre-pro-CRF in PVN, which would unite with
existing pool of CRF get transported into the ME and be rapidly utilized to continue to
elicit ACTH release in pituitary and maintain elevated plasma corticosterone.  It has been
reported by Sharp, et al., (1993), that c-Fos mRNA in hypothalamus was observable after
30 minutes of intraperitoneal nicotine which would confirm continued activation of the
HPA axis.  This regulation of c-Fos by nicotine is modiated through brain stem
neurotransmitters (Valentine, et al., 1996).  The question remains whether or not nicotine
would induce CRF mRNA.  As time passes and approaches 60 minutes or more, would
pre-pro CRF be depleted enough to manifest a decrease in CRF levels for mRNA to be 
induced?  Would the induction of mRNA be counteracted by corticosterone feedback
inhibition?  A higher dose of nicotine will be needed to assess effects on different
hypothalamic nuclei, using microdissections.
Amygdala  
In amygdala macro-dissections, there were no significant treatment and time effects at
1.0 mg/kg nicotine.  Even though there was an apparent increase in CRF levels in 15 and
30 min treatments, these were not significant.  This would suggest that since the whole of
amygdala including the piriform cortex were dissected, CRF that had been released from
the CeA was still in the surrounding neurons, not yet metabolized, therefore detectable.   
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However, the apparent increase in CRF levels in 15 and 30 min treatments may
suggest a typical effect on CRF releasing nuclei, because a significant increase was also
observed in the hypothalamus.  Administration of increasing doses of corticosterone to
adrenalectomized animals has been reported to correspond to as much as five fold increase
in CRF mRNA expression in the CeA of  the amygdala, while CRF mRNA in the
hypothalamus decreased (Makino, et al., 1994; Swanson and Simmons, 1989).  Whether or
not nicotine-induced corticosterone can cause such effects is not known.
Amygdaloid nuclei
In microdissections of amygdaloid nuclei, the time effect that was observed could not
be taken as a clear cut indication of nicotine time effects, because there were no significant
differences between saline treated or untreated rats at these time points.  Treatment for 15
and 30 min with 0.4 mg/kg did not affect levels of CRF in the amygdala for nicotine
versus saline versus untreated animals.  Even though there was a slight increase in CRF for
nicotine treated rats, at 15 minutes compared to saline treated and untreated, this was not
significant.  Therefore, 0.4 mg/kg nicotine slightly elevated CRF in the amygdala but the
levels declined to the levels of untreated rats after 30 minutes.  These findings poissibly
follow the pattern of initial increase in content of CRF as seen with hypothalamus and
amygdala data.  A higher dose of nicotine will be needed to determine if there are any
effects on CRF content in amygdaloid nuclei. 
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Brain stem
Macro-dissected brain stem showed no treatment or time effects on CRF content after
1.0 mg/kg nicotine treatments at all time points, 15, 30 and 60 minutes.  This brain region
was prone to having discrepancies in results due to two reasons;  (I) inconsistencies in
dissections which were more likely to occur with the brain stem and (II) this area was
prone to damage during decapitations and removal from the cranium.  Like all macro-
dissections, in brain stem, effects of nicotine could have been masked by the fact that even
after release from the nuclei, CRF was still in the neighboring CRF areas of the brain stem
and would be detectable.  In addition to the locus coeruleus/parabrachial nucleus (LCPB),
other nuclei including nucleus solitarius, raphe nuclei and dorsal vagal complex express
CRF immunoreactivity (Chappell, et al., 1986).  As discussed earlier, CRF originating
from the amygdala is believed to trigger activation of LC for catecholamine release and
nicotine has been shown to cause noradrenergic activation and release of norepinephrine
into the hypothalamus and amygdala for activation of  CRF release (Fu, et al., 1997; Fu, et
al., 1998; Matta, et al., 1993b; Mitchell, 1993).  Since CRF expressing neurons originate
from the amygdala, significant changes in amygdaloid CRF would need to occur before
changes in the brain stem would be obvious. 
Brain stem nuclei (Locus coeruleus and parabrachial nucleus)
The microdissected brain stem nuclei: locus coeruleus and parabrachial nucleus
showed a nonsignificant decrease in CRF content after 15 minutes treatment.  This initial
decrease in CRF content followed by recovery to untreated levels is an opposite effect
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compared to nicotine’s effects on hypothalamus and amygdala.  This is to be expected
because the brain stem nuclei do not synthesize CRF and once utilized replenishment of
CRF has to come from the amygdala.  A possible role of nicotine to trigger CRF release
which in turn triggers LC activation would be inferred by a decrease in content of CRF
resulting from increased utilization in the brain stem.  A higher dose of nicotine would
need to be utilized to study effects on CRF in brain stem.   
General conclusion
The present study examined effects of nicotine on CRF content in rat amygdala,
hypothalamus and brain stem, using two doses of nicotine 0.4 and 1.0 mg/kg and two
dissection methods at different treatment time points.  The macro-dissection method
revealed significant effects of nicotine (1.0 mg/kg) in the hypothalamus with 15 minutes
treatment.  No significant effects were seen in the amygdala and brain stem.  Time
dependent effects were observed between 15 and 30 minutes nicotine (1.0 mg/kg) treated
rat hypothalami.  The microdissection method using 0.4 mg/kg did not exhibit any
treatment effects with all tested nuclei.  Overall, no clear cut effects were observed with
both dissections and doses of nicotine.  Studies on CRF content in specific nuclei using




For further research, the method of choice would be the cryostat-microdissection
method.  With this method, the nuclei could be accessed individually and characteristic
CRF levels detected for brain region nuclei.  For example: (I) in the amygdala, the central
nucleus (CeA) and basolateral nuclei (BLA) could be micro-punched individually, CRF
levels should vary because the CeA contains more output CRF neurons (cell bodies) while
basolateral has more receptors (terminals), (II) in the hypothalamus, PVN is the main
source of CRF versus median eminence which contains the storage terminals, and other
hypothalamic nuclei could be accessed, and (III) in brain stem, the locus coeruleus and
parabrachial nucleus could be micro-punched separately and other nuclei including
nucleus tractus solitarius and Barrington’s nucleus can be accessed.  Chappell, et al.,
(1986), was able micro-punch out several nuclei in the hypothalamus, amygdala and brain
stem for CRF assessment.  Determining CRF levels in the PVN and ME individually after
15, 30 and 60 minutes of treatment with nicotine (0.4 mg/kg and 1.0 mg/kg), would help
clarify if indeed there are effects on CRF content, and the more rapid method of macro
dissections could be utilized for these nuclei.  Varying doses of nicotine could be utilized
to determine dose response relationships on CRF content in nuclei of the hypothalamus,
amygdala and brain stem.
Molecular biological techniques to examine CRF mRNA would help determine when
the induction of CRF synthesis occurs after nicotine administration.  Microdialysis
techniques can be utilized to monitor CRF release after treatment with lower doses of
nicotine; lower doses of the drug are used for direct delivery into the nuclei.  Microdialysis
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techniques would mostly be useful in the study of earlier time points from 0-20 minutes
after nicotine treatment since nicotine accumulates in the brain within 5 minutes after
intravenous administration.  Effects of acute nicotine on CRF content in the brain could
also be best determined between 5-20 minutes after administration, to coincide with peak
levels.  These earlier time points could be best understood if researched at specified time
intervals for up to 30 or more minutes.
Immunocytochemical techniques and/or receptor binding techniques can be utilized to
determine CRF receptors after acute or chronic nicotine treatment.  The effects of chronic
nicotine using minipumps and/or injections and the effects of nicotine withdrawal can be
determined using these techniques.  Nicotine administered acutely or chronically, and
withdrawal from nicotine all exhibit different effects on animals (Helton, et al., 1993).  In
acute doses, nicotine naive rats could be compared to rats that have been pretreated with
nicotine.  With chronic nicotine treatments, the role that desensitization and tolerance play
on CRF content still needs to be studied.  Cognitive facilitation has been observed in rats
up to four weeks after nicotine treatment (Levin, et al., 1992), therefore, effects of nicotine
withdrawal would help in the elucidation of whether or not CRF is involved in the
addictive effects of nicotine. 
   Future studies must involve the administration of neuronal nAChR antagonists
namely:  mecamylamine, dihydro--erythroidine or chlorisondamine (Dessirier, et al.,
1998; Fu, et al., 1998; Malin, et al., 1994).  This would help confirm whether or not effects
are exerted on neuronal nAChR, that is, the specificity of nicotine.  Whether or not
nicotine stimulates CRF directly or indirectly through brain stem neurotransmitters is yet
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to be documented.  The interaction of CRF systems with cholinergic and noradrenergic
systems and also with other systems could be investigated by injecting agonists or
antagonist for these systems before nicotine injection. 
Nicotine evokes different effects on stressed and unstressed animals and humans
(Balfour, et al., 1975; Donnerer and Lembeck, 1990).  The effects of nicotine-induced
corticosterone will need to be assessed because stress reverses the inhibitory effects of
high levels of corticosterone on CRF, causing a disregulation of the HPA axis (Makino, et
al., 1995).  Hexamethonium, a peripheral nAChR antagonist could be used to determine
the role played in CRF modulation, by nicotine-induced adrenal corticosterone (Bugaski,
et al., 1998; Malin, et al., 1997).  Administration of metyrapone, a corticosterone synthesis
inhibitor, before nicotine treatment would help determine the extent to which CRF is
modulated by nicotine without the input from corticosterone. 
The above mentioned techniques could be applied to stressed rats after acute or
chronic nicotine treatment.  This would demonstrate the effects of nicotine on stressed
rats, and these are expected to vary from normal.  The same techniques could be used on
rats treated prenatally with nicotine to determine if the interaction of nicotine with CRF is
manifest in the offspring.  The plight of prenatal exposure to nicotine; effects on the
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